Program
Mikamo Lecture(Sponsored by Japan Heart Foundation)
Advances in Cardiology and Future Challenges(tentative)
March 12 (Sat) 10:30-11:15 Track 1
Chairperson: |
Ryozo Nagai |
Jichi Medical University |
Speaker: |
Valentin Fuster |
Physician-in-Chief, Mount Sinai Hospital, USA
Director, Mount Sinai Heart, USA
General Director, National Center for Cardiovascular Research, Spain |
Mashimo Memorial Lecture
Taking regulatory T cells into medicine
March 11 (Fri) 14:10-15:00 Track 1
Chairperson: |
Masatsugu Hori |
Osaka International Cancer Institute |
Speaker: |
Shimon Sakaguchi |
Professor, Immunology Frontier Research Center, Osaka University |
Congress Chairperson's Lecture
Something new, something special, all for the patients
March 11 (Fri) 13:30-14:10 Track 1
Chairperson: |
Masunori Matsuzaki |
Emeritus Professor, Yamaguchi University |
Speaker: |
Hiroshi Ito |
Department of Cardiovascular Medicine, Okayama University, Graduate School of Medicine |
President's Lecture
Action and future prospects of the JCS
March 12 (Sat) 13:30-14:00 Track 1
Chairperson: |
Issei Komuro |
Department of Cardiovascular Medicine, The University of Tokyo |
Speaker: |
Ken-ichi Hirata |
President of the Japanese Circulation Society/ Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine |
Special Program
March 13 (Sun) 13:15-14:15 Track 1
Chairperson: |
Hiroshi Ito |
Department of Cardiovascular Medicine, Okayama University, Graduate School of Medicine |
Speaker: |
Michifumi Isoda |
International Research Center for Japanese Studies |
Plenary Session
01.
Novel approaches targeting immune system in atherosclerosis
March 11 (Fri) 08:00-09:30 Track 6
Chairpersons: |
Ken-ichi Hirata |
Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine |
|
Clinton Robbins |
Departments of Laboratory Medicine and Pathobiology and Immunology, University of Toronto, Canada |
State-of-the-art: |
|
Clinton Robbins |
Departments of Laboratory Medicine and Pathobiology and Immunology, University of Toronto, Canada |
Speakers: |
Koh Ono |
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine |
|
Takuo Emoto |
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University School of Medicine |
|
Daiju Fukuda |
Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences |
|
Naoto Sasaki |
Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University |
Chairpersons' Message
Atherosclerotic cardiovascular disease (ASCVD) such as myocardial infarction or stroke have been increasing and become a leading cause of death or loss of healthy life in an aging society. Although the importance of management of traditional risk factors such as LDL-cholesterol, diabetes or hypertension has been established, we cannot fully suppress the incidence of ASCVD until now. Novel strategies in managing and preventing atherosclerosis are desired.
Next generation sequencing based technologies for genomics, transcriptomics, and epigenomics are now increasingly focused on the characterization of individual cells
These single-cell analyses allow researchers to uncover new and potentially unexpected biological discoveries relative to traditional profiling methods that assess bulk populations. Single-cell RNA sequencing (scRNA-seq), for example, can reveal complex and rare cell populations and track the trajectories of distinct cell lineages in development.
These novel technologies enable us to assess complex immune systems leading the formation of atherosclerosis. For example, the heterogeneous component of immune cells in atherosclerosis has been revealed by scRNA-seq. Clonal hematopoiesis in bone marrow was reported to affect the formation of atherosclerosis. A new antigen for atherosclerosis ‘ALDH4A1’ was discovered by a single cell repertoire analysis. We would like to discuss novel progresses targeting immune systems in a research field of atherosclerosis in this symposium.
02.
What is an ideal long-term management of continuous-flow ventricular assist device in the era of destination therapy?
March 11 (Fri) 08:00-09:30 Track 7
Chairpersons: |
Minoru Ono |
Department of Cardiovascular Surgery, Graduate School of Medicine, The University of Tokyo |
|
Jeffrey Teuteberg |
Department of Cardiology, Stanford University, USA |
State-of-the-art: |
|
Jeffrey Teuteberg |
Department of Cardiology, Stanford University, USA |
Speakers: |
Daisuke Yoshioka |
Department of Cardiovascular surgery, Osaka University School of Medicine |
|
Takuya Watanabe |
Department of Transplant Medicine, National Cerebral and Cardiovascular Center |
|
Takako Ozawa |
Yumino Home-Visit Nursing Care Station |
|
Koichiro Kinugawa |
University of Toyama, Toyama |
Chairpersons' Message
Destination therapy (DT) using continuous-flow ventricular assist device (cf-VAD) was approved for health insurance coverage in May, 2021. DT Committee of The Council for Clinical Use of Ventricular Assist Device Related Academic Societies worked up a consensus document for smooth introduction of DT. HeartMate3 is an approved device for DT, and seven hospitals which had participated in DT trial were designated as initial implanting centers. Requirements for caregivers which are strict for BTT were decided to be mitigated for DT, however, evaluation methods of cognitive function were newly mandated to secure a patient understanding ability to a certain level. There was no age limit for DT, but an evaluation of general condition including organ function reserve and 5-year expected survival is required. Bridge to bridge surgery in which a paracorporeal VAD is converted to cf-VAD is approved for DT, though it is thought be more invasive than a primary implant, conditional by a careful patient selection. The J-MACS report revealed that a long-term survival in patients older than 50 years is inferior to that of the younger counterpart. This means that a careful patient selection and post-implantation management is mandatory particularly for those aged over 65, who are deemed to be good candidates for DT. Safety and efficacy have to be demonstrated in the post-market surveillance in order that DT will be recognized as a routine treatment. In this session, reasonable strategies to enable a safe and secure long-term DT treatment will be discussed based on clinical experiences to treat BTT patients and heart-team discussion for future DT therapy in each center.
03.Medical system and interhospital communication for acute aortic emergency: Current status and problems to be solved
March 11 (Fri) 16:00-17:30 Track 11
Chairpersons: |
Nobuyoshi Azuma |
Department of Vascular Surgery, Asahikawa Medical University |
|
Koji Maemura |
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences |
Speakers: |
Yasushi Sakata |
Osaka Universtity Graduate School of Medicine |
|
Tetsuo Yamaguchi |
Department of Cardiovascular Center, Toranomon Hospital |
|
Kenichi Tsujita |
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto |
|
Shinji Miyamoto |
Department of Cardiovascular Surgery, Oita University |
|
Morimasa Takayama |
Sakakibara Heart Institute・Tokyo CCU network Council |
|
Nobuyoshi Azuma |
Department of Vascular Surgery, Asahikawa Medical University |
|
Masanari Kuwabara |
Ministry of Health, Labour and Welfare, Japan |
Chairpersons' Message
Although survival rate of acute aortic emergency including acute aortic dissection and ruptured aneurysm has been gradually improved by establishment of treatment techniques, advancement of perioperative care, and applying endovascular devices, there is still wide room to improve the survival rate and quality of patient care.
The Japanese National Plan for Promotion of Measures Against Cerebrovascular and Cardiovascular Disease was published in 2020, which intensively mentions about medical service system for acute aortic emergency. JCS has immediately responded to the law and announced the second five-year plan “Stop CVD” that describes the importance of emergency medical service renovation by proposing network formation to select adequate hospital and shorten the door to intervention time. Interhospital communication as well as communication between cardiovascular surgeons and cardiologists through the network may be important especially in the countryside.
Meaningful discussion with reporting specific issues and ingenuities by speakers in this session hopefully contributes to improve medical system for the acute aortic emergency in each area.
04.
COVID-19 and Cardiovascular Disease
March 11 (Fri) 13:30-15:00 Track 12
Chairpersons: |
Koichi Node |
Department of Cardiovascular Medicine Saga University |
|
Takuya Kishi |
Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare |
State-of-the-art: |
|
Valentin Fuster |
Physician-in-Chief, Mount Sinai Hospital, USA
Director, Mount Sinai Heart, USA
General Director, National Center for Cardiovascular Research, Spain |
Speakers: |
Hideki Ishii |
Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine |
|
Hiroki Kitakata |
Department of Cardiology, Keio University School of Medicine |
|
Nobuhiro Murata |
Department of Cardiology, Nihon University School of Medicine |
|
Hiroaki Kawano |
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences |
|
Yugo Yamashita |
Kyoto University Hospital |
Chairpersons' Message
COVID-19 is rampant all over the world, and as of February 2021, the cumulative number of SARS-CoV-2 positives is about 420,000 and the cumulative number of deaths is about 7,500. With COVID-19, it has been reported that the aggravation rate and mortality rate increase with aging, and the majority of COVID-19 deaths in Japan are elderly people in their 60s or older. Coexistence of cardiovascular disease in COVID-19 has been reported to be associated with increased mortality from COVID-19. Especially in the elderly, there are few complications of cardiovascular disease, and there is concern that the prognosis may worsen due to the overlapping risk of aggravation. On the other hand, regarding the relationship between cardiovascular disease and COVID-19, not only the coexistence of cardiovascular disease is a poor prognosis factor, but also SARS-CoV-2 infection directly or indirectly damages the cardiovascular system. It has been reported to cause coronavirus-related cardiovascular disease. In this session, we will discuss the existence of new coronavirus-related cardiovascular diseases, the existence of cardiovascular diseases as aggravating factors in COVID-19, and the effects of COVID-19 epidemics and lockdown on cardiovascular diseases.
05.Autonomic nerves in arrhythmia / heart failure; pathophysiology and treatment
March 11 (Fri) 16:00-17:30 Track 12
Chairpersons: |
Hiroshi Morita |
Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences |
|
Peng-Sheng Chen |
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, USA |
State-of-the-art: |
|
Peng-Sheng Chen |
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, USA |
Speakers: |
Miho Miyoshi |
Oita University Department of Cardiology and Clinical Examination |
|
Yuichi Hori |
Department of Cardiology, Dokkyo Medical University Saitama Medical Center |
|
Masakazu Miyamoto |
Department of Cardiovascular Medicine Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences |
|
Kyoko Soejima |
Department of Cardiovascular Medicine Kyorin University Hospital |
Chairpersons' Message
Recently, the significances of autonomic nervous system [ANS] on various heart disease have been well recognized. ANS is important as an arrhythmic trigger and an aggravating factor of heart failure [HF]. In arrhythmic diseases, activities of sympathetic and parasympathetic nerves trigger atrial and ventricular tachyarrhythmias and arrhythmic storm. Then, autonomic nerve modulation is useful for therapy of various arrhythmias in addition to antiarrhythmic agents and a radiofrequency catheter ablation those directly modulate arrhythmic foci or circuits. 𝛽-blocker is a basic ANS modulation therapy in arrhythmias. From the 1990’s, cardiac sympathetic nerve denervation has been used for the therapy of congenital long QT syndrome. Recently, usefulness of GP ablation in atrial fibrillation and denervation of cardiac and renal sympathetic nerve systems in malignant ventricular tachyarrhythmias with organic heart diseases have been reported. In HF, sympathetic activation aggravates myocardial injury and results in worsening of HF. 𝛽-blocker is established as an essential ANS modulation in HF. Since parasympathetic inactivation is also an aggravating factor of HF, various devices that stimulate spinal cord, auricle or neck carotid body to activate parasympathetic nerve have been investigated. Expertise of molecular and genetic factors, evaluation methods and modulative therapies in cardiac ANS are now developing. We expect to know new findings and have useful discussions on cardiac ANS.
06.Utilization of AI in cardiovascular imaging
March 12 (Sat) 08:00-09:30 Track 6
Chairpersons: |
Masataka Sata |
Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences |
|
Jagat Narula |
Icahn School of Medicine at Mount Sinai, USA |
State-of-the-art: |
|
Jagat Narula |
Icahn School of Medicine at Mount Sinai, USA |
Speakers: |
Junko Honye |
Cardiovascular Center, Kikuna Memorial Hospital |
|
Kenya Kusunose |
Department of Cardiovascular Medicine, Tokushima University Hospital |
|
Yuki Saito |
Division of Cardiology, Department of Medicine, Nihon University School of Medicine |
|
Yuki Sahashi |
Depertment of Cardiology, Gifu University School of Medicine |
Chairpersons' Message
Artificial intelligence (AI) refers to technology that allows computers to mimic human cognitive functions, learn from collected data, and solve problems. In the field of cardiovascular imaging, the aim of AI is to diagnosis, predict outcomes, and select optimal treatments. AI for cardiovascular imaging can provide new clinical insights by combining big data sources with clinical information from electronic medical records and mobile health devices. AI has the potential to advance cardiovascular imaging, because of its ability to handle large amounts of input data.
In this symposium, we would like to describe the role of AI in cardiovascular imaging, including echocardiography, nuclear medicine imaging, computed tomography, and cardiac magnetic resonance, and discuss current applications of AI in automation, disease recognition, and prediction.
07.Artificial Intelligence in Cardiovascular Medicine: New perspectives and challenges
March 12 (Sat) 08:00-09:30 Track 7
Chairpersons: |
Satoshi Yasuda |
Tohoku University Graduate School of Medicine |
|
Khung Keong Yeo |
National Heart Centre Singapore, Singapore |
State-of-the-art: |
|
Khung Keong Yeo |
National Heart Centre Singapore, Singapore |
Speakers: |
Kunihiro Nishimura |
NCVC |
|
Kotaro Nochioka |
Department of Cardiovascular Medicine, Tohoku University Hospital |
|
Kengo Kusano |
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center |
|
Hiroshi Akazawa |
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo |
Chairpersons' Message
Artificial intelligence (AI) and machine learning are poised to influence the cardiovascular medicine. nearly every aspect of the human condition, and cardiology is not an exception to this trend. AI is bringing a paradigm shift, powered by increasing availability of data and rapid progress of analytics techniques, in the three major areas of early detection and diagnosis, treatment, as well as outcome prediction and prognosis evaluation. This session will review selected applications of these methods in cardiovascular filed to date and identify how cardiovascular medicine could incorporate artificial intelligence in the future.
08.
Comprehensive Treatment Strategy for Atrial Fibrillation to Extend Healthy Life Expectancy
March 12 (Sat) 08:00-09:30 Track 19
Chairpersons: |
Kazuo Minematsu |
Medical Corporation ISEIKAI |
|
Wataru Shimizu |
Department of Cardiovascular Medicine, Graduate School of Medicine, Nippon Medical School |
Speakers: |
Hidehiro Kaneko |
Department of Cardiovascular Medicine, The University of Tokyo |
|
Yasuhiro Hamatani |
Department of Cardiology, National Hospital Organization Kyoto Medical Center |
|
Ken Okumura |
Division of Cardiology, Saiseikai Kumamoto Hospital |
|
Yu-ki Iwasaki |
The Department of Cardiovascular Medicine, Nippon Medical School |
|
Nobuhiro Ikemura |
Department of Cardiology, Keio University School of Medicine |
|
Tasuku Yamamoto |
Department of Cardiovascular Medicine, Tokyo Medical and Dental University |
Chairpersons' Message
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and its prevalence increases with age. AF is associated with the risk of developing stroke 5 times higher, cognitive impairment 3 times higher, and heart failure (HF) 2 times higher than sinus rhythm. Since these 3 all cause long-term care in elderly patients, it is extremely important to develop a comprehensive treatment strategy for the extension of healthy life expectancy. In the cardiovascular area, catheter ablation (CA) has become popular as a rhythm control therapy. CA is reported to be associated with better prognosis and less HF hospitalization in patients with HF, and is indicated to be associated with less stroke than medical therapy (rate or rhythm control). However, the effectiveness by CA is limited in patients with persistent or chronic AF, thus comprehensive treatment for comorbidities and underlying cardiovascular diseases in addition to pharmacological therapy is strongly recommended. On the other hand, in cerebrovascular area, appearance of thrombectomy has dramatically changed the acute therapy for cardiogenic cerebral embolism. Moreover, the Basic Plan to Promote Stroke and Cardiovascular Disease Control Programs published by the Japanese Government has included the building of seamless medical system from rehabilitation to home medical care. In this plenary session, expert cardiologists and cranial neurologists are welcome to discuss a comprehensive treatment strategy for AF management.
09.
Latest CMR diagnostic strategy for myocardial hypertrophy
March 12 (Sat) 16:00-17:30 Track 6
Chairpersons: |
Hajime Sakuma |
Department of Radiology, Mie Univeristy Hospital |
|
Chiara Bucciarelli-Ducci |
Royal Brompton and Harefield Hospitals, Guy's and St Thomas NHS Trust and King's College London, UK |
State-of-the-art: |
|
Chiara Bucciarelli-Ducci |
Royal Brompton and Harefield Hospitals, Guy's and St Thomas NHS Trust and King's College London, UK |
Speakers: |
Shoko Nakagawa |
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center |
|
Kenichi Hongo |
Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine |
|
Yasuyo Taniguchi |
Department of Cardiology, Hyogo Brain and Heart Center at Himeji |
|
Yasuki Hen |
Department of Cardiology, Sakakibara Heart Institue Clinic |
Chairpersons' Message
Cine MRI and late gadolinium-enhanced MRI have been widely used for the evaluation of patients with myocardial diseases by cardiac magnetic resonance (CMR). Recently, CMR parametric mapping, which can quantitatively evaluate myocardial T1 relaxation time, extracellular volume (ECV), and myocardial T2 relaxation time, has emerged, increasing the importance of CMR in the diagnosis and prognosis of patients with myocardial diseases. Parametric mapping is particularly useful in the diagnosis of cardiac amyloidosis (T1 prolongation) and Fabry disease (T1 shortening), where there is little overlap compared to the measurements in normal myocardium. On the other hand, the magnitude of T1 change in cardiomyopathy is relatively limited, and the T1 relaxation time may vary depending on the pulse sequences and imaging parameters. In this session, we will discuss what kind of tissue changes parametric mapping reflects, the accuracy and reproducibility of T1 and T2 measurements, and the usefulness of parametric mapping in myocardial diseases showing myocardial hypertrophy, aiming to expand the use of CMR parametric mapping in Japan.
10.
Desicion making an appropriate candidate of invasive treatment in elderly patients with severe aortic stenosis
March 12 (Sat) 16:00-17:30 Track 8
Chairpersons: |
Akira Shiose |
Department of Cardiovascular Surgery, Kyushu University |
|
Masanori Yamamoto |
Toyohashi Heart Center |
Speakers: |
Tomohiko Taniguchi |
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital |
|
Yoku Kikuchi |
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine |
|
Masamichi Iwasaki |
Department of Cardiology, Hyogo Prefectural Awaji Medical Center |
|
Ryosuke Higuchi |
Department of Cardiology, Sakakibara Heart Institute |
|
Tsukasa Okai |
Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine |
|
Hideaki Kanzaki |
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center |
|
Hiroyuki Irie |
Department of Cardiovascular Surgery, Chikamori Hospital |
Chairpersons' Message
It is global agreement that the invasive therapy should be considered for patients with severe aortic stenosis (AS) regardless of the patient's age such as octogenarians because of their poor prognosis. A less invasive transcatheter aortic valve implantation (TAVI) has emerged as a therapeutic option for elderly patients with AS, and the indications for TAVI are rapidly expanding based on the clinical data. Similarly, surgical aortic valve replacement (SAVR) is classical established therapy for elderly patients with AS. With the development of device technology and improvement the early safety of the procedure, the indication of both SAVR and TAVI is expanding in this decade. However, an adequate pre-screening or risk stratification should be required before the procedure. In addition, the decision making for appropriate invasive therapy candidates should be clinically determined by balancing the risk and benefit. In this session, we would share the current status of SAVR and TAVI therapy in Japan and discuss the possible advantages of invasive therapy for AS patients.
11.T2DM as cardiovascular disaease:
Pathophysiology and new treatment strategy
March 13 (Sun) 08:00-09:30 Track 1
Chairpersons: |
Hiroshi Ito |
Department of Cardiovascular Medicine, Okayama University, Graduate School of Medicine |
|
E. Dale Abel |
University of Iowa, Carver College of Medicine, USA |
State-of-the-art: |
|
E. Dale Abel |
University of Iowa, Carver College of Medicine, USA |
Speakers: |
Keisuke Kojima |
Division of Cardiology, Department of Medicine, Nihon University School of Medicine |
|
Takehiro Hata |
Department of Cardiology, Tokyo Womens Medical University |
|
Yasuko K.Bando |
Department of Cardiology, Nagoya University School of Medicine |
|
Hiromitsu Kanamori |
Department of Cardiology, Gifu University Graduate School of Medicine |
Chairpersons' Message
Until now, type 2 diabetes (T2DM) has been classified as a metabolic disease, although it is a risk factor for cardiovascular disease, and has been treated by diabetologists to control blood glucose. This trend was changed by the results of cardiovascular outcome trials (CVOTs), which were conducted as safety trials for new diabetes drugs. By reducing the hard endpoints of cardiovascular death, myocardial infarction, and stroke, it was clarified that GLP-1RA and SGLT2 inhibitors have a preventive effect on cardiovascular events beyond glycemic control. Based on the results of CVOTs, the guidelines for diabetes treatment were rewritten in Europe and the United States, and it was clarified that the selection of diabetes drugs is important for improving the prognosis of high-risk T2DM patients. SGLT2 inhibitors have been shown to be able to improve the prognosis of HFrEF patients and have been added to the essential treatment of heart failure. In addition, results of CVOTs provide a new perspective on the pathogenic mechanism of T2DM-induced arteriosclerosis, heart failure, and atrial fibrillation. The pathogenic mechanisms include endothelial dysfunction due to hyperglycemia, dyslipidemia as well as AGE / RAGE accumulation, complications of hypertension, persistent microinflammation, abnormal energy metabolism at mitochondrial level, sympathetic nerve hyperactivity, RAA system enhancement and hyperinsulinemia, which enhances cell proliferation and Na retention. And elucidation of the pathology leads to new therapeutic targets. This plenary session discusses the latest pathological mechanism why T2DM causes cardiovascular disease and provides common treatment strategies for diabetologists and cardiologists to prevent cardiovascular events and improve prognosis of T2DM patients.
12.Overview & Future Perspective of MINOCA
March 13 (Sun) 10:30-12:00 Track 7
Chairpersons: |
Kenichi Tsujita |
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University |
|
Gaku Nakazawa |
Kindai University Faculty of Medicine |
State-of-the-art: |
|
Thomas J. Ford |
Department of Cardiology, Gosford Hospital, Gosford, Australia |
Speakers: |
Taku Inohara |
Department of Cardiology, Keio University School of Medicine |
|
Takamasa Iwai |
Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center |
|
Masanobu Ishii |
Department of Cardiovascular Medicine, Kumamoto University Hospital |
|
Kiyotaka Hao |
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine |
Chairpersons' Message
Although several years have passed since the concept of myocardial infarction with nonobstructive coronary arteries (MINOCA), it remains a puzzling clinical entity. Whereas the prevalence of MINOCA has been globally reported to be approximately 6% of MI patients with relatively better prognosis, a Japanese nationwide administrative database in the super-aging society demonstrated their higher prevalence of MINOCA up to 10% and higher in-hospital mortality in patients with MINOCA, indicating that the in-hospital mortality depends on the pathogenesis of MINOCA. Moreover, compared to patients with MI with obstructive coronary artery disease, MINOCA is a group of heterogeneous diseases arising from a variety of potential causes. Therefore, MINOCA was considered a “working diagnosis” analogous to heart failure, prompting further evaluation regarding its underlying mechanisms.
In this fascinating plenary session, we would like to summarize the previous global and domestic evidences about the MINOCA, and discuss on the current status of MINOCA practice and future perspective.
13.Unsolved issues and future perspective in ACHD: Beyond the Guidelines
March 13 (Sun) 13:15-14:45 Track 6
Chairpersons: |
Teiji Akagi |
Department of Cardiovascular Medicine, Okayama University |
|
Michael Gatzoulis |
Royal Brompton & Harefield NHS Trust, and the National Heart & Lung Institute, Imperial College, UK |
State-of-the-art: |
|
Michael Gatzoulis |
Royal Brompton & Harefield NHS Trust, and the National Heart & Lung Institute, Imperial College, UK |
Speakers: |
Norihisa Toh |
Department of Cardiovascular Medicine, Okayama University |
|
Ichiro Sakamoto |
Department fo Cardiovascular Medicine, Kyushu University Hospital |
|
Yumi Shiina |
St.Luke's International Hospital |
|
Hideo Ohuchi |
National Cerebral and Cardiovascular Center |
Chairpersons' Message
Adult congenital heart disease has become an unavoidable reality for adult cardiologists. As has been speculated in the past, the proportion of congenital heart disease requiring management by cardiologists is increasing in moderate to severe heart disease. Postoperative cases of complex heart disease, mainly cyanotic heart disease, have become an avoidable problem in adulthood, including arrhythmia, heart failure, and pulmonary hypertension. These are the issues that cardiologists face in their daily practice, however, in the field of adult congenital heart disease, the cardiac problems of individual patients are different. In addition, each patient often undergoes different surgical treatment options, further contributing to the diversity of postoperative conditions. The diversity of cardiac diseases complicates the treatment strategy and requires personalized therapy for each patient. In addition, the number of cases of each cardiac disease is limited, making homogeneous evaluation in large numbers of patients difficult. Adult congenital heart disease is a new group of diseases that have not been encountered in the field of cardiology, and surgical approaches have changed over time, such as the Fontan procedure. Although Japanese Circulation Society or International guidelines have established a standard of the management of adult congenital heart disease, there are various areas in which evidence is low, and the establishment of appropriate treatment guidelines is expected to change in the future. In this session, we would like to clarify the clinical issues that have not been clarified yet due to limited evidence in adult congenital heart disease and discuss the future prospects of these issues and new therapeutic modalities based on the latest findings.
14.
Progress of genome medicine in cardiovascular diseases
March 13 (Sun) 13:15-14:45 Track 7
Chairpersons: |
Issei Komuro |
The University of Tokyo |
|
Patrick E. Ellinor |
Massachusetts General Hospital / Harvard Medical School, USA |
State-of-the-art: |
|
Patrick E. Ellinor |
Massachusetts General Hospital / Harvard Medical School, USA |
Speakers: |
Kaoru Ito |
Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical Sciences |
|
Hayato Tada |
Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences |
|
Kenzaburo Nakajima |
National Cerebral and Cardiovascular Center |
|
Seitaro Nomura |
The University of Tokyo Hospital |
Chairpersons' Message
Progress of cancer research has enabled us to understand the underlying mechanisms of cancer development. Cancer is induced by the mutations of genes which are usually involved in cell growth and these genes are called as driver genes. Many molecular targeted drugs have been developed and prognosis of cancer has been remarkably improved. Nowadays, molecular targeted drugs are selected after identifying the driver genes. Although various environmental factors play important roles in the development of cardiovascular diseases, genetic factors are also critically involved in cardiovascular diseases. In the near future, genomic medicine will be done for cardiovascular diseases; genetic factors will be determined and then treatment will be decided based on the genetic factors. Advances in genomic medicine of cardiovascular diseases will be discussed in this plenary session.
Symposium
01.
The strategic distinction for CLTI among BSX, EVT and medications
March 11 (Fri) 08:00-09:30 Track 8
Chairpersons: |
Katsuyuki Hoshina |
Department of Vascular Surgery, The University of Tokyo |
|
Yoshimitsu Soga |
Department of Cardiology, Kokura Memorial Hospital |
Keynote Lecture: |
|
Toshio Takayama |
Department of Vascular Surgery, The University of Tokyo |
Speakers: |
Yosuke Hata |
Cardiovascular Center, Kansai Rosal Hospital |
|
Taku Kato |
Department of Cardiology, Rakuwakai Otowa Hospital |
|
Kota Shukuzawa |
Division of Vascular Surgery, Department of Surgery ,The Jikei University School of Medicine |
|
Shinya Sasaki |
Depertment of Cardiology, Saka General Hospital |
Chairpersons' Message
It is not easy for patients with CLTI (chronic threatening limb ischemia) to consider which is the optimal practice among surgical revascularization, endovascular therapy and medication (including primary amputation). The goal of CLTI is not successful revascularization, but wound healing as well as the improvement of its mortality. The current guideline from western countries were revised to indicate that life expectancy of >2 years is an important factor for the initial revascularization in CLTI patients. However, this concept is extremely limited because there is no obvious definition of 2-year life expectancy. Furthermore, the evidence regarding Japanese CLTI patients including many dialysis patients is insufficient to apply in a clinical setting. Recently, the effectiveness of EVT for infra-popliteal lesion in CLTI has been published. However, high restenosis and high reintervention rate is still big issue.
Through this CLTI symposium, to achieve effective complete wound healing and for better life prognosis, we would like to discuss what approaches should we adopt to improve wound healing, the border of strategic appropriate revascularization and multidisciplinary approach, the perspective and risk stratification in CLTI, and the role of adjuvant therapy (lumbar sympathectomy, hyperbaric oxygen therapy、carbon dioxide bath、blood apheresis…)
02.Breakthroughs in the pathophysiology and treatment of HFpEF
March 11 (Fri) 08:00-09:30 Track 9
Chairpersons: |
Kazuhiro Yamamoto |
Department of Cardiovascular Medicine, and Endocrinology and Metabolism, Tottori University |
|
Barry A Borlaug |
Mayo Clinic, USA |
Keynote Lecture: |
|
Barry A Borlaug |
Mayo Clinic, USA |
Speakers: |
Taijyu Satoh |
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine |
|
Shota Shirotani |
Department of Cardiology, Tokyo Women's Medical University |
|
Shungo Hikoso |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Yoshiharu Kinugasa |
Department of Cardiovascular Medicine and Endocrinology and Metabolism, Tottori University |
Chairpersons' Message
No treatment strategy has been found to improve the life expectancy of HFpEF patients in contrast to HFrEF. One of the main reasons for this is that investigations about pathophysiology and effective therapeutic approach in HFpEF have been conducted in terms of one-size-fits-all, despite the fact that the pathophysiology of HFpEF is diverse partly because HFpEF is common in the elderly. Recently, in order to solve this problem, HFpEF has been divided into several clusters by phenomapping and other methods, and attempts have been made to investigate the pathophysiology of each cluster. Some studies have shown that racial differences should be taken into account for clustering, and thus, studies with Japanese patients are awaited. In terms of treatment, the efficacy of some drug therapies and non-drug therapies such as interatrial shunt device is being investigated. Targeting comorbidities that affect the severity of HFpEF has also received attention. Interventions for atrial fibrillation, atrial functional mitral regurgitation caused by atrial fibrillation, skeletal muscle dysfunction, and nutritional disorders, and other approaches from various angles are being tried. In this session, we would like to discuss how far we have progressed in elucidating the pathophysiology of HFpEF using new approaches, and what methods of therapeutic intervention are being explored, based on the latest findings.
03.
Beyond the clinical practice guidelines: New horizons in pulmonary arterial hypertension therapies
March 11 (Fri) 08:00-09:30 Track 11
Chairpersons: |
Yoshihiro Fukumoto |
Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine |
|
Takeshi Ogo |
National Cerebral and Cardiovascular Center |
Speakers: |
Kohtaro Abe |
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences |
|
Yoichi Takaya |
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences |
|
Nobuhiro Yaoita |
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine |
|
Hanako Kikuchi |
Department of Cardiovascular Medicine, Kyorin University Hospital |
|
Yoshikazu Nakaoka |
Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute |
Chairpersons' Message
Treatment of pulmonary arterial hypertension (PAH) has improved dramatically these 20 years, based on the extensive basic, translational, and clinical research. The use of three type pulmonary vasodilators have significantly improved the prognosis of the patients with PAH. The 6th World Symposium on Pulmonary Hypertension proposed PAH treatment strategy of initial combination therapy based on the evidences of better outcome. However, the etiology of PAH is diverse and various factors are involved in the development and progression of the disease. Outcome with PAH specific treatment is still not always sufficient. It is our mission to solve these problems to improve the prognosis and quality of life in PAH such as refractory PAH, the difference in individual response to treatment, unknown mechanisms of PAH development and progression. Personalized medicine on the basis of each pathogenesis of PAH to achieve could lead better outcome on top of current standard treatment. In this symposium, we would like to discuss possible future PAH treatment based on the results of basic, translational, and clinical research for PAH beyond current treatment guidelines.
04.
Recent Advances of Nonpharmacological Therapy for Persistent Atrial Fibrillation-Topics for Left Atrial Appendage Occlusion Device, Catheter Ablation and Surgical Therapy
March 11 (Fri) 08:00-09:30 Track 12
Chairpersons: |
Kengo Kusano |
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center |
|
Hiroshi Tada |
Department of Cardiovascular Medicin, Faculty of Medical Sciences, University of Fukui |
Speakers: |
Yohei Sotomi |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Takeshi Sasaki |
Department of Cardiology, Heart Rhythm Center |
|
Masato Fukunaga |
Department of Cardiology, Kokura Memorial Hospital |
|
Hiroshi Kubota |
Department of Cardiovascular Surgery, Kyorin University |
|
Takashi Kakuta |
National Cerebral and Cardiovascular Research Center |
|
Takashi Noda |
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine |
Chairpersons' Message
Atrial fibrillation (AF) is associated with the cerebral/systemic embolism as well as heart failure development. Recently, nonpharmacological therapy of catheter ablation for AF has been demonstrated a great advantage for reducing the cerebral embolism or the heart failure development, and the number of catheter ablation has dramatically increased in Japan. Catheter ablation strategy for paroxysmal AF is nearly established, but AF is a progressive disease and atrial remodeling causes AF persisted, leading the mitral regurgitation deteriorated or easy to create the clot formation in the atrium. Accordingly, effective and safety strategy for advanced persistent AF is needed in the clinical setting. In this session, the topics of nonpharmacological therapy for persistent AF, regarding the recent advances of catheter ablation, left atrial appendage occlusion and surgical approaches will be demonstrated by experts, and we will make a discussion about the effective and safety strategy for persistent AF.
05.
Position statement on endomyocardial biopsy
March 11 (Fri) 16:00-17:30 Track 8
Chairpersons: |
Kazufumi Nakamura |
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences |
|
Takayuki Inomata |
Department of Cardiovascular Medicine, Niigata University School of Medical and Dental Sciences, Niigata |
|
Keynote Lecture: |
|
Petar M. Seferovic |
Serbian Academy of Sciences and Arts, University of Belgrade Faculty of Medicine, Serbia |
Speakers: |
Keiko Ohta-Ogo |
Department of Pathology, National Cerebral and Cardiovascular Center |
|
Masayoshi Yamamoto |
Department of Cardiology, Faculty of Medicine, University of Tsukuba |
|
Shiro Nakamori |
Department of Cardiology, Mie University |
|
Shohei Kataoka |
Department of Cardiology, Tokyo Women's Medical University |
|
Koji Nakagawa |
Department of Cardiovascular Medicine, Okayama University Hospital |
Chairpersons' Message
The endomyocardial biopsy method using a catheter, which was developed by Dr. Konno and Dr. Sakakibara in Japan in 1962, has become popular worldwide as a useful test method. It is now an indispensable test method for the diagnosis of heart transplant rejection and the diagnosis of myocarditis and cardiomyopathy. In recent years, new treatments have been developed for cardiomyopathy-related diseases and diagnostic methods using multimodality imaging have advanced, and it is time to renew our views on endomyocardial biopsy. In 2021, the Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society also released a new “Position statement on endomyocardial biopsy”. In this symposium, we would like to discuss the views on indications, procedures, interpretation and utilization of the results of endomyocardial biopsy while adding topics such as new disease concepts, treatment methods, and multimodality imaging.
06.
Takayasu arteritis: Pathogenesis, current diagnosis and treatment
March 11 (Fri) 13:30-15:00 Track 9
Chairpersons: |
Mitsuaki Isobe |
Sakakibara Heart Institute |
|
R. Haner Direskeneli |
Marmara University, School of Medicine, Turkey |
Keynote Lecture: |
|
R. Haner Direskeneli |
Marmara University, School of Medicine, Turkey |
Speakers: |
Haruhito Uchida |
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Chronic Kidney Disease and Cardiovascular Disease |
|
Yasuhiro Maejima |
Department of Cardiovascular Medicine, Tokyo Medical and Dental University |
|
Takashi Funaki |
Department of Cardiology, Sakakibara Heart Institute |
|
Yoshikazu Nakaoka |
Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute |
|
Mitsuaki Isobe |
Sakakibara Heart Institute |
Chairpersons' Message
Takayasu arteritis is a refractory arteritis affecting aorta and other systemic organs mainly in young females. The etiology is still unknown but recent investigation reveals some molecular aspects associated with the pathogenesis. The primary point of diagnosis of Takayasu arteritis is to suspect the existence of this disease, since the symptoms are quite nonspecific and specific clinical test is not present to date. Definite diagnosis is usually made from the pattern of arterial imaging such as FDG-PET/CT, CT angiography and MR angiography. Prednisolone is the first line immunosuppressant for this disease, however, two thirds of patients experience relapse of inflammation during the tapering. New immunosuppressive agents including infliximab and tocilizumab have been increasingly applied. Still these agents are not effective in some patients and diagnosis of flare up during tocilizumab treatment is an emerging serious issue. Vascular repair is required in about 25% of patients. The utility of intravascular treatment for occlusive arterial lesion has not been established because of very high rate of restenosis. In this symposium we expect to introduce and discuss current knowledge on this disease from the aspects of basic research, epidemiology, diagnosis, medical and surgical treatment.
07.
Genomic medicine for arrhythmic diseases
March 11 (Fri) 16:00-17:30 Track 9
Chairpersons: |
Tetsushi Furukawa |
Medical Research Institute, Tokyo Medical and Dental University |
|
Koonlawee Nademanee |
Pacific Rim Electrophysiology Research Institute, Thailand |
Keynote Lecture: |
|
Koonlawee Nademanee |
Pacific Rim Electrophysiology Research Institute, Thailand |
Speakers: |
Keiko Sonoda |
Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center |
|
Kensuke Ihara |
Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University |
|
Yukiko Nakano |
Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences |
|
Keisuke Usuda |
Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences |
Chairpersons' Message
Genome research on arrhythmic diseases began in the 1990s when ion channel genes were identified as causative genes for long QT syndrome and Brugada syndrome by linkage analysis. Since the phenotype of ion channel gene mutations can be analyzed with high precision using the patch clamp method, genomic research has advanced ahead of other diseases. Since then, the spread of next-generation sequencing technology has dramatically advanced the understanding of familial arrhythmia diseases, and the existence of modifier-gene polymorphisms as well as causative gene mutations is becoming clear. In addition, many disease-sensitive gene polymorphisms for common arrhythmia diseases such as atrial fibrillation have been identified by the development of whole genome-related analysis (GWAS). Genomic medicine, in which the information obtained from these genomic studies is applied in clinical practice, is also being carried out. Long QT syndrome is treated differently depending on the causative gene. For atrial fibrillation, high-risk patients are identified from genomic risk scores calculated from multiple atrial fibrillation susceptibility gene polymorphisms, and early detection of atrial fibrillation onset can be detected with long-term Holter ECG monitoring, and wearable devices such as Apple Watch, etc. This symposium will cover the state-of-the-art precision medicines for arrhythmic diseases based on these genomic research information.
08.
Optimal diagnostic method for coronary microcirculation
March 11 (Fri) 13:30-15:00 Track 11
Chairpersons: |
Naoya Matsumoto |
Nihon University Hospital, Department of Cardiology |
|
Nobuhiro Tanaka |
Tokyo Medical University Hachioji Medical Center |
Speakers: |
Yoshiharu Higuchi |
Cardiovascular Division, Osaka Police Hospital |
|
Jun Takahashi |
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine |
|
Hisanori Kosuge |
Department of Cardiology, Tokyo Medical University |
|
Satsuki Noma |
Department of Cardiovascular Medicine, Nippon Medical School |
|
Akiko Sakai |
Department of Cardiology, Tokyo Women's Medical University |
Chairpersons' Message
Evidence of myocardial ischemia is a requirement for coronary revascularization. Fractional flow reserve (FFR) examination or stress myocardial perfusion modalities (myocardial scintigraphy, CT, MRI, etc.) are recently used for the detection of coronary artery stenotic lesion causing myocardial ischemia. The positive threshold of the FFR is 0.75 -0.8 with myocardial scintigraphy as the SOT, but the discrepancy between FFR and myocardial scintigraphy is a common phenomenon in daily clinical practice. In recent years, it has also been called Ischemia with no obstructive coronary artery disease (INOCA), which is partly due to the so-called coronary microvascular dysfunction (CMD) in arterioles. The prognosis for patients with CMD is poor and has been associated with reduced left ventricular diastolic function or HFpEF. Epicardial coronary angioplasty in patients with CMD does not always improve CMD, therefore multimodality diagnosis is important. Invasively, CMD evaluation includes Index of Microcirculatory Resistance (IMR) and noninvasive measurement of coronary blood flow at rest and stress using PET/CT (coronary flow reserve: CFR) is common.
In this symposium, we would like to discuss the selection of modalities, methods of stress, and treatments as optimal diagnostic methods for CMD.
09.
Can aortic valve repair be the standard procedure for patients with aortic regurgitation? Current indications
March 11 (Fri) 16:00-17:30 Track 21
Chairpersons: |
Yutaka Okita |
Cardio-Aortic Center, Takatsuki General Hospital |
|
Satoshi Nakatani |
Saiseikai Senri Hospital |
Speakers: |
Yoshihiro Seo |
Department of Cardiology, Nagoya City University |
|
Hidekazu Tanaka |
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine |
|
Tomoki Shimokawa |
Department of Cardiovascular Surgery, Sakakibara Heart Institute |
|
Tatsuhiko Komiya |
Department of Cardiovascular Surgery, Kurashiki Central Hospital |
|
Takashi Kunihara |
Department of Cardiac Surgery, The Jikei University School of Medicine |
Chairpersons' Message
Many techniques of aortic valve repair for patients with aortic regurgitation have been reported since 1960s, however, these procedures have not been popularized because the early or long-term outcome was inferior to mitral valve repair. Since 1990s, techniques of aortic valve sparing root replacement have developed, many clinical experiences of aortic valve sparing method have been accumulated mainly in young patients. Recent development of concise knowledge of aortic root anatomy, trans-esophageal echocardiography, and CT scans were contributed. In this symposium, clinical applications of the aortic valve repair technique, including preoperative morphological or quantitative diagnosis of aortic regurgitation, operative procedures and outcomes, in patients with aortic regurgitation should be discussed.
10.
Current state and challenges of big data analysis
March 12 (Sat) 10:30-12:00 Track 6
Chairpersons: |
Satoaki Matoba |
Department of Cardiovascular Medicine, Graduate School of Medical Science Kyoto Prefectural University of Medicine |
|
Yoshihiro Miyamoto |
National Cerebral and Cardiovascular Center |
Keynote Lecture: |
|
Kunihiro Matsushita |
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA |
Speakers: |
Shun Kohsaka |
Department of Cardiology Keio University School of Medicine |
|
Yoshitaka Iwanaga |
National Cerebral and Cardiovascular Center |
|
Yuichiro Okushi |
Department of Cardiovascular Medicine, Tokushima University Hospital |
|
Takashi Shiroto |
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine |
|
Koshiro Kanaoka |
Center for Cerebral and Cardiovascular Disease Information, National Cerebral and Cardiovascular Center |
Chairpersons' Message
The Second Five-Year Plan to Overcome Stroke and Cardiovascular Disease includes the promotion of registration as one of main five projects. Big data, which is characterized by a large number of cases, relatively quick data conversion, and a large variety of data, is expected to be utilized for understanding the actual state of medical care, improving the quality of medical care, and conducting research. DPC data used in the comprehensive medical payment system can also be considered big data, and Japanese Circulation Society has made DPC data collected through the Japanese Registry Of All cardiac and vascular Diseases (JROAD) available for use in many studies. Registries, such as the JCVSD and J-PCI, with a high degree of completeness can also be considered big data, and many research results have been reported from them. However, many issues remain in the current big data, such as the lack of information on the long-term prognosis of patients and the difficulty in linkage of information on the same patient from different medical institutions. In this symposium, we would like to have you introduce the current status of research using big data and propose remaining issues and their solutions.
11.
Exploring the possibilities of remote cardiac rehabilitation
March 12 (Sat) 10:30-12:00 Track 12
Chairpersons: |
Shigeru Makita |
Saitama Medical University International Medical Center |
|
Shin-ichiro Miura |
Department of Cardiology, Fukuoka University School of Medicine |
Speakers: |
Atsuko Nakayama |
Sakakibara Heart Institute |
|
Tsuyoshi Suzuki |
Yumino Heart Clinic Mitaka |
|
Yuko Kato |
Department of Cardiovascular Medicine, The Cardiovascular Institute |
|
Eisuke Amiya |
Department of Therapeutic Strategy for Heart Failure, University of Tokyo, Tokyo |
|
Yutaka Kimura |
Kansai Medical University, Health Science Center |
Chairpersons' Message
Telemedicine is drawing attention as a result of the spread of the new coronavirus infection. Research has progressed on the application of telemedicine in the field of cardiac rehabilitation. Outpatient cardiac rehabilitation currently has a low rate of patients’ continuing their hospital visits. Furthermore, outpatient cardiac rehabilitation involves group instruction, which contributes to crowding. Thus, it is expected that "remote cardiac rehabilitation" will become increasingly important in the future. Based on reports to date, the efficacy and safety of home-based cardiac rehabilitation are equivalent to those of outpatient cardiac rehabilitation, and it is recommended as class II in the guidelines for rehabilitation in cardiovascular disease revised in 2021. However, from the viewpoint of safety, necessity, and effectiveness, a remote system that patients, families, and medical staff can use with peace of mind is needed. At this symposium, the researchers will report on cardiovascular diseases and exercise programs for which "remote cardiac rehabilitation" is indicated, and their implementation status. Furthermore, we would like to discuss current issues and how to overcome them in terms of two-way communication, exercise equipment, sensors, surveillance systems, and medical costs.
12.
Current status and challenges for reduction of in-hospital and out-hospital mortality from acute myocardial infarction
March 12 (Sat) 10:30-12:00 Track 19
Chairpersons: |
Tetsuya Amano |
Aichi Medical University |
|
Yoshihiro Morino |
Iwate Medical University |
Speakers: |
Yasunori Ueda |
Cardiovascular Division, NHO Osaka National Hospital |
|
Riku Arai |
Division of Cardiology, Department of Medicine, Nihon University School of Medicine |
|
Kenichi Tsujita |
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University |
|
Satoshi Takeuchi |
Department of Cardiology, Tohoku University |
|
Mitsuaki Sawano |
Department of Cardiology, Keio University School of Medicine |
Chairpersons' Message
There is no doubt about improvements of life prognosis by emergent revascularization (i.e. primary percutaneous coronary intervention) as an initial treatment of acute myocardial infarction (AMI). However, actual in-hospital mortality has not been improved for the past several years, which requires additional measures for regional disparities of rates of emergent revascularization, out-of-hospital triage, and medical service systems during recovery as well as chronic periods in order to further reduce the mortality. Moreover, “The Basic Act on extension of healthy life expectancy for strokes and cardiac diseases (No. 105, Dec. 14th, Heisei 30)”, established in last year, requires discussion of actions on prevention, diagnosis, treatment, and rehabilitation for reduction of mortality of cardiovascular diseases with adequate temporal perspectives. Furthermore, any effects of coronavirus crisis on AMI treatment must be considered at the timing of “with Corona”. In this session, re-evaluating current status of AMI with real-world data, we would like to discuss on the issues of any potential challenges for reduction of mortality of AMI considering entire time courses including at prevention, acute, recovery, and chronic phases.
13.
Transcatheter and Surgical Intervention for Secondary Mitral Regurgitation caused by LV dysfunction; MitraClip/TMVR or Valve repair/replacement
March 12 (Sat) 08:00-09:30 Track 23
Chairpersons: |
Yoshiro Matsui |
Hanaoka Seishu Memorial Hospital |
|
Nozomi Watanabe |
Cardiovascular Physiology, University of Miyazaki Faculty of Medicine |
Speakers: |
Yuki Izumi |
Sakakibara Heart Institute, Department of Cardiology |
|
Atsushi Suzuki |
Department of Cardiology, Tokyo Women's Medical University |
|
Makoto Amaki |
National Cerebral and Cardiovascular Center |
|
Koji Furukawa |
Department of Cardiovascular Surgery, Faculty of Medicine, University of Miyazaki |
|
Satoru Wakasa |
Department of Cardiovascular and Thoracic Surgery, Hokkaido University Graduate School of Medicine |
Chairpersons' Message
Management of functional mitral regurgitation (MR) is always challenging based on various basic condition with generally poor prognosis due to reduced LV function. Heterogeneous valve geometry causing functional MR makes the therapeutic assessment more complicated, and it is difficult to make a ‘standard’ in the assessment of the major contributor of refractory heart failure. This session aims to help understanding the mechanisms and pathophysiology of the complex disease and to get up-to-date knowledge from the prognostic insights of functional MR, and then to discuss the indication of surgical intervention and transcatheter surgery including edge-to-edge MV repair and TMVR. Customized treatment considering multiple factors including the unique valve characteristics and each patient’s basic condition is required in the assessment of functional MR, and we hope that we can get an active discussion for this topic from the various clinical insights.
14.
Challenge for treatment of heart failure based on new molecular pathogenesis
March 12 (Sat) 16:00-17:30 Track 5
Chairpersons: |
Masafumi Yano |
Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine |
|
Koichiro Kuwahara |
Shinshu University School of Medicine |
Keynote Lecture: |
|
Joseph A. Hill |
UT Southwestern Medical Center, USA |
Speakers: |
Tetsuro Oda |
Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine |
|
Eiki Takimoto |
Department of Cardiovascular Medicine, The University of Tokyo |
|
Koichiro Kuwahara |
Department of Cardiovascular Medicine, Shinshu University |
|
Hiroyuki Takahama |
National Cerebral and Cardiovascular Center |
Chairpersons' Message
Recently, the effectiveness of new therapeutic agents for heart failure such as ARNI and SGLT2 inhibitors has been proved by large-scale RCTs, and these agents are already clinically available in Japan, and it is expected that the prognosis of heart failure patients will be improved. However, the prognosis of patients with heart failure is still poor, and a fundamental treatment for heart failure has not been developed yet. Recent detailed studies at the cellular and molecular levels have revealed that a wide range of factors are involved in the pathophysiology of heart failure, such as activation of neurological and humoral factors associated with inflammation and oxidative stress, metabolic disorders, intracellular Ca2+ handling disorders, cell proliferation / cell death, etc. Molecules and systems that link the heart to other organs and tissues can also be therapeutic targets. In this session, we would like to explore new treatments for heart failure based on the latest research on the molecular mechanism of heart failure.
15.
Progress in Heart Failure Imaging
March 12 (Sat) 13:30-15:00 Track 6
Chairpersons: |
Yasushi Sakata |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Kaoru Dohi |
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine |
Keynote Lecture: |
|
Jagat Narula |
Icahn School of Medicine at Mount Sinai, USA |
Speakers: |
Satomi Yashima |
Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine |
|
Tomohito Ohtani |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Masashi Amano |
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center |
|
Yoshihiro Seo |
Department of Cardiology, Nagoya City University |
Chairpersons' Message
Regardless of the underlying etiology, heart failure is a clinical syndrome that causes systemic and/or pulmonary congestion and organ hypoperfusion due to the loss of compensation for reduced cardiac pump function. From this perspective, it should be emphasized that all areas of cardiovascular imaging which can assess clinical conditions and pathophysiology of heart failure are regarded as “heart failure imaging”. The choice of heart failure imaging modality depends on the disease trajectory and treatment strategy for each patient, and therefore proper use of multiple heart failure imaging is required in the assessment of hemodynamic profiles as well as heart failure stages under varying disease conditions during the time course of heart failure. In addition, the development of imaging strategy helps physicians predict patient outcomes and provide optimal palliative care. We would like to discuss current challenges and future directions in heart failure imaging using new technologies such as hybrid imaging, molecular imaging and IoT.
16.
Re-intervention for congenital heart disease in adulthood
March 12 (Sat) 13:30-15:00 Track 8
Chairpersons: |
Isao Shiraishi |
National Cerebral and Cardiovascular Center |
|
Lucy Youngmin Eun |
Pediatric Cardiology, Yonsei University Severance Hospital, Korea |
Keynote Lecture: |
|
Lucy Youngmin Eun |
Pediatric Cardiology, Yonsei University Severance Hospital, Korea |
Speakers: |
Mike Saji |
Department of Cardiology, Sakakibara Heart Institute |
|
Kazuto Fujimoto |
Department of Pediatric Cardiology National Cerebral and Cardiovascular Center |
|
Nobuhiro Nishii |
Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences |
|
Keiko Toyohara |
Department of Pediatric Cardiology and Adult Congenital Heart Disease, Tokyo Women's Medical University |
|
Hajime Ichikawa |
Department of Pediatric Cardiovascular Surgery, National Cerebral and Cardiovascular Center |
Chairpersons' Message
Advances in diagnosis and surgical operation have rescued many child patients with congenital heart disease, and now approximately 90% of patients have grown up to adulthood. These patients are able to spend a satisfactory life during the growing childhood. However, after adulthood, they start to suffer from novel symptoms including intractable arrhythmias and progressive heart failure due to complications and residual lesions of the surgical operation. In addition, patients after Fontan procedure often develop multi-organ disorders called failing Fontan. Therefore, accurate detection of these newly emerging lesions and re-intervention at an appropriate timing is essential to improve the prognosis of the patients with adult congenital heart disease. In this symposium, we would like to discuss timing and method of re-intervention for adult congenital heart disease patients from the stand point of surgical operation, catheter intervention, and catheter ablation.
17.
Diagnostic and therapeutic strategy for CCS following ISCHEMIA TRIAL
March 12 (Sat) 13:30-15:00 Track 12
Chairpersons: |
Yuji Ikari |
Tokai University |
|
Genichi Sakaguchi |
Department of Cardiovascular Surgery, Kindai University Hospital |
Speakers: |
Gaku Nakazawa |
Kindai Univeristy Faculty of Medicine |
|
Takayuki Ohno |
Department of Cardiovascular Surgery, Mitsui Memorial Hospital, Tokyo |
|
Shinya Goto |
Department Medicine Cardiology, Tokai University School of Medicine |
|
Takayuki Warisawa |
St. Marianna University School of Medicine Yokohama City Seibu Hospital |
|
Shun Kohsaka |
Department of Cardiology Keio University School of Medicine |
Chairpersons' Message
ISCHEMIA Trial is the randomized trial comparing the two groups: initially conservative treatment group vs immediate revascularization group. There was no significant difference in 2-year survival. Notably, a fourth of the patients in the conservative group had received PCI or CABG for within 4 years. The immediate revascularization group had more angina relief and reduced the risk of MI. The sub-analysis suggested that the immediate revascularization group improved the prognosis of the patients with the history of heart failure.
Currently, revascularization is justified when ischemia is proved. On the other hand, it should be deferred for non-ischemic vessels. The trial showed that the medical treatment can be prior to the immediate revascularization even if ischemia is proven. However, one-fourth of the patients in the conservative group needed revascularization within 4 years.
Given these evidences, we need to rethink the strategy of diagnosis and therapy for CCS. We expect this session to organize the evidences and to show the future direction to go.
18.
How to clear the hurdles of carrier - Challenge for the sustainable future
March 12 (Sat) 13:30-15:00 Track 17
Chairpersons: |
Shiro Uemura |
Kawasaki Medical School, Cardiovascular Medicine |
|
Yasuko K Bando |
Department of Cardiology, Nagoya University |
Commentators: |
|
Yoshihiro Fukumoto |
Cardiovascular Medicine, Kurume University School of Medicine |
|
Makiko Taniyama |
Okayama University |
Speakers: |
Noriko Fukue |
Department of Cardiology, Tokuyama Medical Association Hospital |
|
Noriko Nonoguchi |
Department of Cardiology, Kyorin University |
|
Fumi Yamagami |
Yumino Heart Clinic Shibuya |
|
Ryoko Kitada |
Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine |
|
Ayako Okada |
Department of Cardiology, Shinshu University School of Medicine |
Chairpersons' Message
In Japan, number of female students enrolled in medical school has exceeded one-third, and the proportion of female doctors is expected to steadily increase. On the other hand, the field of cardiology, where the pandemic of heart failure becomes more intense with the super-aging population, is an area of expertise where the proportion of female doctors is remarkably low. Irrespective of age or gender, how the doctors continue and improve their careers is an indispensable viewpoint in terms of realizing work style reforms. Especially female doctors in Japan have two social hurdles due to the consciousness of gender roles known as "Unconsciousness bias". It is often difficult to balance work and life such as childbirth, childcare, etc., and female doctors are often forced to interrupt their career around 10 years after graduation of medical school, namely, their mid-30s. This is known as a peculiar M-shaped curve phenomenon in which nearly 20% of these young female doctors facing the crisis of their career. Another hurdle is the lack of female leaders in Japanese medical society. Due to another aspect of the “Unconsciousness bias” that is common among women, that is, the subconsciousness and customs of the person whose virtue is humility, there are few opportunities for women, including those in the medical community, to become leaders. In most Western countries, various systems such as the quota system have already been realized, but Japan is too far from the gender quality to escape from the lowest lank of the OECD countries. Improving the working environment in the medical field and developing female leaders are two-wheeled, Unless such improvement is attained, women's participation and career continuation at the level of developed countries cannot be achieved.
At this symposium, we will clarify the current situation and issues with both female and male experts of junior doctors and senior doctors on how to overcome the barriers of career continuation.
19.
Collaboration with cardiologists in the intensive care unit: from cardiovascular management to infection control
March 13 (Sun) 08:00-09:30 Track 6
Chairpersons: |
Naoki Sato |
Department of Cardiovascular Medicine, Kawaguchi Cardiovascular and Respiratory Hospital |
|
Tomonori Itoh |
Iwate Medical University |
Keynote Lecture: |
|
Petar M. Seferovic |
Serbian Academy of Sciences and Arts, University of Belgrade Faculty of Medicine, Serbia |
Speakers: |
Akihiro Shirakabe |
Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital |
|
Yuji Nishimoto |
Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center |
|
Shun Kohsaka |
Department of Cardiology, Keio University School of Medicine |
|
Yuichiro Kashima |
Department of Emergency and Critical Care Medicine, Shinshu University |
Chairpersons' Message
Multidisciplinary treatment of cardiovascular emergencies is increasingly required due to the increasing number of elderly patients. In addition to cardiovascular diseases, we are increasingly required to deal with infectious diseases, such as pneumonia and sepsis, and multi-organ disorders, such as renal dysfunction. In order to respond more quickly and accurately to these complex conditions, it is extremely important to collaborate with intensivists. Particularly in the COIVD19 pandemic, an approach to cardiovascular complications, including myocarditis and thrombosis, should be necessary. We would like to provide an opportunity to think about more robust cardiovascular intensive care based on our experience of dealing with this problem through cooperation between cardiologists and intensivists.
20.
How to start treatment in the intensive care unit from the pre-hospital stage
March 13 (Sun) 10:30-12:00 Track 6
Chairpersons: |
Yoshio Tahara |
National Cerebral and Cardiovascular Center |
|
Tomoyuki Endo |
Tohoku Medical and Pharmaceutical University Hospital |
Keynote Lecture: |
|
Migaku Kikuchi |
Dokkyo Medical University |
Speakers: |
Jin Kirigaya |
Yokohama City University Medical Center |
|
Megumi Yamamuro |
Intensive Care Unit of Saiseikai Kumamoto Hospital |
|
Hiroshi Imamura |
Department of Emergency and Critical Care Medicine, Shinshu University |
|
Jun Nakata |
Division of Cardiovascular Intensive Care, Nippon Medical School Hospital |
Chairpersons' Message
Patients admitted to the intensive care unit suffer from a wide variety of diseases. In particular, cardiovascular emergencies such as acute coronary syndromes, heart failure, and acute aortic syndrome require detailed systemic management including the effort to reduce the time to initiate the radical treatment for the causative disease and admit to the intensive care unit, complication management, and hemodynamic assessment.
The effectiveness of quality management in the intensive care unit is built upon the centralization of the patients appropriate for intensive care. For this purpose, collaboration among general practitioners, prehospital ambulance crews, emergency room physicians, and cardiologists is important.
In this session, we will discuss (1) regional registries of cardiovascular diseases requiring intensive care, (2) regional cardiovascular emergency medical care systems (hospital selection, medical control, CCU network), (3) triage in the emergency department (in-hospital systems, establishment of heart teams), (4) emergency treatment of critical cardiovascular illnesses (innovations for early initiation of treatment), (5) hemodynamics evaluation (e.g. ultrasound) and indications for assisted circulation devices (IABP, ECMO, IMPELLA), and (6) measures to assess severity and improve outcome (SOFA score, APACHE score, targeted temperature management, etc.).
In order to establish a system that enables faster and more appropriate transport from emergency scenes to the specialized cardiovascular medical institutions, we hope that the presentations in this session will give useful ideas about the prehospital information and the applicable intervention before hospital admission and contribute to the establishment of a medical care delivery system based on the actual conditions of each region.
21.
Cutting-edge Science in Stem Cell, Gene Therapy, and Regeneration for Cardiovascular Disease
March 13 (Sun) 08:00-09:30 Track 7
Chairpersons: |
Masaki Ieda |
University of Tsukuba |
|
Yoshinori Yoshida |
Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University |
Keynote Lecture: |
|
Deepak Srivastava |
Gladstone Institutes, USA |
Speakers: |
Yoshinori Yoshida |
Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University |
|
Shuichiro Higo |
Department of Medical Therapeutics for Heart Failure, Osaka University Graduate School of Medicine |
|
Masataka Yokoyama |
Department of Molecular Diagnosis, Chiba University Graduate School of Medicine |
|
Masaki Ieda |
Department of Cardiology, Faculty of Medicine, University of Tsukuba |
Chairpersons' Message
The establishment of human iPS cells was announced in 2007, and 2022 will mark the 15th year. During this period, major developments have been made in various fields such as CRISPR-Cas9 genome editing, single-cell analysis technology, and AI. Until now, the elucidation of the pathophysiology of cardiovascular diseases and the development of treatments have been carried out mainly using model animals and human cell lines. It is now expected that these new basic technologies will be combined and used for these purposes near future. In addition, as a vaccine treatment for covid19, new strategies such as mRNA vaccine and adenovirus vector vaccine have been developed, which are changing the real world significantly. New effective gene therapies have been developed for various diseases and some of them have shown dramatic effects. On the other hand, how about cardiac regenerative medicine? Myocardial regeneration using hematopoietic stem cells and cardiac stem cells heated in the 2000s showed moderate effects in clinic, which is mainly due to paracrine effects rather than direct differentiation of these cells into cardiomyocytes, as revealed by many subsequent scientific verifications. In the future, myocardial regeneration using pluripotent stem cells such as iPS cells, direct cardiac reprogramming, and rejuvenation treatment of cardiomyocytes may be warranted. At this symposium, we would like you to present the latest findings from wide range of cardiovascular research fields.
22.
Front line of pharmacological therapy for heart failure
March 13 (Sun) 08:00-09:30 Track 11
Chairpersons: |
Yoshihiko Saito |
Department of Cardiovascular Medicine, Nara Medical University |
|
Hiroyuki Tsutsui |
Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University |
Speakers: |
Satoshi Shoji |
Department of Cardiology, Hino Municipal Hospital |
|
Yuichiro Minami |
Department of Cardiology, Tokyo Women's Medical University |
|
Koichiro Kinugawa |
University of Toyama |
|
Hidekazu Kondo |
Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine |
|
Shigeki Kobayashi |
Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine |
Chairpersons' Message
Based on the elucidation of the pathophysiology of heart failure through basic research and evidence based on large-scale clinical trials, the pharmacological treatment for heart failure has been shifted from conventional therapy with diuretics and positive inotropes to the inhibition of neurohumoral activation. In addition to ACE inhibitor, angiotensin receptor blocker (ARB), mineralocorticoid receptor antagonist (MRA), and β-blockers for heart failure with reduced ejection fraction (HFrEF), newer drugs have been approved such as the If channel inhibitor ivabradine, the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril valsartan, and the SGLT-2 inhibitors dapagliflozin and empagliflozin. Furthermore, the efficacy of the soluble guanylate cyclase (sGC) stimulator, vericiguat, and the cardiac myosin activator, omecamtiv mecarbil, was also demonstrated in HFrEF. The efficacy and safety of these drugs are now being evaluated based on the experience in the daily clinical practice. Despite advances in the drug treatment for heart failure, its prognosis remains still poor, and basic research aimed to develop more effective therapeutic agents is being actively conducted. In this symposium, we would aim to present the recent findings on heart failure drug treatment from both clinical and basic research and to overview the present and future of heart failure treatment.
23.
Challenges and Opportunities in Cancer Therapeutics-Related Cardiovascular Disorders (CTRCD)
March 13 (Sun) 13:15-14:45 Track 5
Chairpersons: |
Hironobu Minami |
Medical Oncology / Hematology, Kobe University Graduate School of Medicine |
|
Kazuhiro Sase |
Clinical Pharmacology & Regulatory Science, Juntendo University |
Keynote Lecture: |
|
Michael G. Fradley |
University of Pennsylvania, USA |
Speakers: |
Yuko Fukuda |
Department of Cardiovascular Medicine, Hyogo Cancer Center |
|
Kenta Yamada |
Cardiovascular Center, International University of Health and Welfare Mita Hospital |
|
Yoshihito Saijo |
Department of Cardiology, Tokushima University Hospital |
|
Akito Shindo |
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo |
Chairpersons' Message
Progress in medical care for cancer has greatly contributed to lower mortality rates in affected patients, resulting in increasing importance for cancer survivorship care in Japan and throughout the world. Results of epidemiological studies indicate that one of the most important causes of death among cancer survivors is cardiovascular disease (CVD). In addition to common risk factors for CVD and cancer, there is also growing awareness of cancer treatment-related cardiovascular disorders (CTRCD) associated with traditional and modern treatment strategies.
Cardio-oncology is a rapidly developing interdisciplinary field. By sharing the goal of improving patient outcomes, cardiologists and oncologists are tackling new challenges, including the prevention, diagnosis, and treatment of CTRCD. Initially, the need for a team-based approach was recognized at the field level in specialized cancer centers and teaching hospitals. However, as it gradually developed into collaboration at the national and academic levels, the lack of evidence as a basis for clinical practice guidelines and the need for basic, clinical, and epidemiological research became apparent.
In this symposium, with the Japanese Society of Clinical Oncology (JSMO) and the Japanese Society of Oncology and Cardiology (JSMO), we would like to share achievements from the up-to-date cancer therapeutics and discuss the current status and future directions of CTRCD to facilitate interdisciplinary collaboration between oncologists and cardiologists further.
24.
Basic biology of aging
March 13 (Sun) 15:45-17:15 Track 5
Chairpersons: |
Tohru Minamino |
Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine |
|
Vicente Andrés |
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Spain |
Keynote Lecture: |
|
Vicente Andrés |
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Spain |
Speakers: |
Yuichi Oike |
Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University |
|
Ichiro Manabe |
Department of Systems Medicine, Chiba Univesity |
|
Haruya Yamane |
Cardiovascular Division, NHO Osaka National Hospital |
|
Koji Ikeda |
Department of Epidemiology for Longevity and Regional Health, Kyoto Prefectural University of Medicine |
Chairpersons' Message
In the current era of 100-year lifespans, in Japan we are experiencing a superaged society that the world has never seen before. One of the most important issues in this context is that the discrepancy between the healthy lifespan and the average lifespan has continuously increased, even though significant progress has been made in medical treatments. It is well accepted that age-associated increases in cardiovascular disease, such as ischemic heart disease and stroke, contribute to this discrepancy. Because the incidence of cardiovascular disease increases with advancing age and therefore this type of disease per se could be a part of pathological aging phenotypes in older populations, many researchers suggest that a novel therapeutic strategy for cardiovascular disease should target molecular mechanisms of organismal aging. Several countries, including Japan, are currently conducting national projects with the aim to elucidate the molecular mechanisms of aging. For example, age-associated accumulation of senescent cells in tissues has been shown to provoke chronic inflammation and thereby contribute to pathological aging, and researchers are now trying to develop senolytics that specifically eliminate senescent cells from aged tissues and thus improve pathological aging. An age-associated increase of somatic mutations in hematopoietic cells has been reported to lead to clonal hematopoiesis, which promotes chronic inflammation and causes cardiovascular disease. Promoting DNA repair could be another strategy to improve pathological aging. In this symposium, we will discuss recent progress in aging research and future directions towards developing novel treatments for cardiovascular disease.
25.
Progress in Medical Device Development -From Non-clinical to Clinical Evaluation-
March 13 (Sun) 13:15-14:45 Track 9
Chairpersons: |
Masato Nakamura |
Toho University, Ohashi Medical Center, Division of Cardiovascular Center |
|
Masanori Nakamura |
Nagoya Institute of Technology |
Keynote Lecture: |
|
Kiyotaka Iwasaki |
Cooperative Major in Advanced Biomedical Sciences, Graduate School of Advanced Science and Engineering, Waseda University |
Speakers: |
Isao Shiraishi |
Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center |
|
Takeshi Machino |
Department of Cardiology, University of Tsukuba |
|
Tomohiko Shindo |
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine |
Chairpersons' Message
The COVID-19 pandemic is still ongoing although vaccination is progressing gradually. Domestic development of vaccine is yet to catch up (May 2021), and the safety-net of vaccine procurement from abroad has been rendered unstable. Besides vaccine development, Japan is also behind the world in the development of medical devices. Reportedly, in 2015, Japan experienced an excess of imports of about 800 billion yen in the trade balance for medical devices. Medical devices are now indispensable to support medical care along with pharmaceutical products. Medical devices have a wide variety of produces, from inexpensive ones such as syringes and thermometers to expensive ones such as CT and MRI. One says that 500,000 to 600,000 types of medical devices are currently in use in clinical practice, while medical drugs in use are 15,000. Clinical and non-clinical evaluations of medical devices prior to the market release are essential not only to verify the safety and performance including the clinical benefit but also to speed up the regulatory approval process. From the perspective of animal welfare, non-clinical evaluations will gather more attentions than clinical evaluations. The Japanese Circulation Society and the Japan Society of Mechanical Engineers have signed the collaborative agreement, aiming at mutual understanding between clinical practice and engineering. This session is organized under this collaborative agreement. In this session, we would like to discuss issues concerned with medical device development in light of non-clinical and clinical evaluations. We hope that this session will help solve the problems in the development of medical devices for cardiovascular diseases.
Special Symposium
01.Optimal Treatment for Tricuspid Regurgitation Based on the Morphology of the Tricuspid Valve
March 12 (Sat) 10:30-12:00 Track 13
Chairpersons: |
Kiyoyuki Eishi |
Department of Cardiovascular Surgery, Nagasaki University |
|
Masao Daimon |
The University of Tokyo Hospital |
Speakers: |
Makoto Miyake |
Department of Cardiology, Tenri Hospital |
|
Norihisa Toh |
Department of Cardiovascular Medicine, Okayama University |
|
Takashi Miura |
Division of Cardiovascular Surgery, Nagasaki University |
|
Hiroto Utsunomiya |
Department of Cardiovascular Medicine, Hiroshima University |
02.Challenges for management of severe mitral regurgitation in patients on dialysis -Efficacy and limitations of surgical and transcatheter treatment-
March 12 (Sat) 08:00-09:30 Track 22
Chairpersons: |
Takashi Matsumoto |
Department of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital |
|
Akihiko Usui |
Nagoya University Graduate School of Medicine Department of Cardiac Surgery |
Speakers: |
Shimon Kurasawa |
Nagoya University Graduate School of Medicine |
|
Akihiro Isotani |
Department of Cardiology, Kokura Memorial Hospital |
|
Wataru Kato |
Department of Cardiovascular Surgery, Japanese Red Cross Nagoya Daini Hospital |
|
Shunsuke Kubo |
Department of Cardiovascular Medicine, Kurashiki Central Hospital |
03.New approaches to myocardial disease from basic and clinical research
March 12 (Sat) 13:30-15:00 Track 13
Chairpersons: |
Satoaki Matoba |
Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine |
|
Gary D. Lopaschuk |
Faculty of Medicine & Dentistry, University of Alberta, Canada |
Speakers: |
Gary D. Lopaschuk |
Faculty of Medicine & Dentistry, University of Alberta, Canada |
|
Satoshi Gojo |
Department of Regenerative Medicine, Kyoto Prefectural University of Medicine |
|
Takeshi Tokudome |
Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute |
|
Takaaki Abe |
Tohoku University |
|
Yasushi Okazaki |
Juntendo University, RIKEN |
04.JCS-JJC 10th Anniversary
March 12 (Sat) 16:00-17:30 Track 13
Chairpersons: |
Yasuko K Bando |
Department of Cardiology, Nagoya University |
|
Minako Yamaoka-Tojo |
Kitasato University |
Speakers: |
Keiko Yamauchi-Takihara |
Health and Counseling Center, Osaka University |
|
Reiko Tsukahara |
Tokyo General Hospital, Department of Cardiology |
|
Junko Honye |
Kikuna Memorial Hospital |
|
Akiko Chishaki |
Fukuoka Dental College, Fukuoka Nursing College |
|
Tomoko Tomioka |
South Miyagi Medical Center |
|
Chizuko Kamiya |
National Cerebral and Cardiovascular Center, Suita |
05.Polypharmacy in the management of cardiovascular diseases
March 13 (Sun) 15:45-17:15 Track 9
Chairpersons: |
Takeshi Yamashita |
The Cardiovascular Institute |
|
Masato Eto |
University of Tokyo, Department of Medical Education |
Speakers: |
Takuto Arita |
Department of Cardiovascular Medicine, The Cardiovascular Institute |
|
Ko Yamamoto |
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto |
|
Takayuki Inomata |
Department of Cardiovascular Medicine, Niigata University School of Medical and Dental Sciences, Niigata |
|
Fumihiro Mizokami |
National Center for Geriatrics and Gerontology |
|
Shota Hamada |
Institute for Health Economics and Policy |
AHA-JCS Joint Symposium
How do we struggle against residual risk?
March 13 (Sun) 08:00-09:30 Track 5
Chairpersons: |
Junya Ako |
Kitasato University |
|
Donald M. Lloyd-Jones |
Northwestern University Feinberg School of Medicine, USA |
APSC-JCS Joint Symposium
Imaging-based physiological assessments; which one and how to use in daily clinical practice
March 12 (Sat) 08:00-09:30 Track 13
Chairpersons: |
Takashi Akasaka |
Department of Cardiovascular Medicine, Wakayama Medical University |
|
Jack Wei Chieh Tan |
National Heart Centre Singapore, Singapore |
KSC-JCS Joint Symposium
Social promotion and emergency care in ischemic heart disease emergency
March 12 (Sat) 08:00-09:30 Track 5
Chairpersons: |
Yoshio Kobayashi |
Chiba University |
|
Jang-Whan Bae |
Chungbuk National University, College of Medicine, Department of Internal Medicine (Cardioloy Division), Korea |
CSC-JCS Joint Symposium
Recent advance in atrial fibrillation treatment
March 11 (Fri) 08:00-09:30 Track 5
Chairpersons: |
Akihiko Nogami |
Department of Cardiology, Faculty of Medicine, University of Tsukuba |
|
Shu-Lin Wu |
GuangDong Provincial People’s Hospital |
ESC-JCS Joint Symposium
Case Discussions with the Masters in Japan and Europe: Interventions of Mitral or Tricuspid Valve
March 13 (Sun) 15:45-17:15 Track 5
Chairperson: |
Yoshihiro Morino |
Iwate Medical University |
ACC-JCS Joint Symposium
MINOCA: What do we know?
March 13 (Sun) 10:30-12:00 Track 5
Chairperson: |
Satoshi Yasuda |
Tohoku University Graduate School of Medicine |
Special Lecture
01.Rethink the QOL of CAD patients
March 12 (Sat) 13:30-14:00 Track 7
Chairperson: |
Junya Ako |
Kitasato University |
Keynote Lecture: |
|
John A Spertus |
University of Missouri - Kansas City and Saint Luke's Mid America Heart Institute, USA |
02.Role of Echocardiography in Structure Intervention
March 12 (Sat) 14:00-14:30 Track 7
Chairperson: |
Chisato Izumi |
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center |
Keynote Lecture: |
|
Rebbeca T. Hahn |
Colombia University, USA |
03.The Changing Landscape of Atherosclerosis
March 12 (Sat) 16:00-16:30 Track 7
Chairperson: |
Ken-ichi Hirata |
Kobe University Graduate School of Medicine |
Keynote Lecture: |
|
Peter Libby |
Brigham and Women's Hospital / Harvard Medical School, USA |
04.Management of spontaneous coronary artery dissection (SCAD)
March 12 (Sat) 16:40-17:10 Track 7
Chairperson: |
Kazushige Kadota |
Cardiovasecular Medicine, Kurashiki Centeral Hospital |
Keynote Lecture: |
|
Jacqueline Saw |
Vancouver General Hospital, University of British Columbia, Canada |
05.Molecular Imaging in Assessing Cardiovascular Pathology
March 13 (Sun) 10:30-11:00 Track 8
Chairperson: |
Hiroshi Ito |
Department of Cardiovascular Medicine, Okayama University |
Keynote Lecture: |
|
Jonathan R. Lindner |
Oregon Health & Science University, USA |
06.Molecular Imaging in Cardiovascular Disease
March 13 (Sun) 11:10-11:40 Track 8
Chairperson: |
Yasuchika Takeishi |
Department of Cardiovascular Medicine, Fukushima Medical University |
Keynote Lecture: |
|
Takahiro Higuchi |
Department of Nuclear Medicine, CHFC, University of Wuerzburg, Germany |
Educational Lecture
Arrhythmia and cardiac electrophysiology to the future -fiction or non-fiction?-
March 12 (Sat) 11:30-12:00 Track 1
Chairperson: |
Tohru Ohe |
Okayama City Hospital |
Speaker: |
William G. Stevenson |
Cardiovascular Division, Department of Medicine, Vanderbilt University Medical Center, USA |
Special Session
01.Device therapy for Stroke prevention. Current situation and newer evidence
March 11 (Fri) 08:00-09:30 Track 19
Chairpersons: |
Hidehiko Hara |
Division of Cardiovascular Medicine, Toho University Ohashi Medical Center |
|
Kazunori Toyoda |
National Cerebral and Cardiovascular Center |
Speakers: |
Teiji Akagi |
Department of Cardiovascular Medicine, Okayama University |
|
Hideaki Kanazawa |
Department of Cardiology, Keio University School of Medicine |
|
Yoshifumi Nakajima |
Division of Cardiology, Department of Internnal Medicine, Iwate Medical University |
|
Yasuyuki Iguchi |
Department of Neurology, The Jikei University School of Medicine, Tokyo |
|
Sohei Yoshimura |
Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center |
02.Cardiogenic shock and mechanical cardiac support
March 11 (Fri) 08:00-09:30 Track 21
Chairpersons: |
Masaharu Ishihara |
Department of Cardiovascular and Renal Medicine, Hyogo College of Medicine |
|
Yasuchika Takeishi |
Department of Cardiovascular Medicine, Fukushima Medical University |
Speakers: |
Junichi Yamaguchi |
Department of Cardiology, Tokyo Women's Medical University |
|
Kazuoki Dai |
Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital |
|
Tetsuya Matoba |
Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University |
|
Keita Saku |
Department of Cardiovascular Dynamics, National Cerebral and Cardiovascular Center, Suita |
03.How to manage patients with syncope; up to date
March 12 (Sat) 10:30-12:00 Track 5
Chairpersons: |
Haruhiko Abe |
Department of Heart Rhythm Management, University of Occupational and Environmental Health |
|
Junjiroh Koyama |
Division of Cardiology, Saiseikai Kumamoto Hospital, Cardiovascular Center |
Keynote Lecture: |
|
Michele Brignole |
IRCCS Istituto Auxologico Italiano, Department of Cardiology, Italy |
Speakers: |
Masaru Suzuki |
Depertment of Emergency Medicine, Tokyo Dental College Ichikawa General Hospital |
|
Toshiyuki Furukawa |
Syncope Unit, St. Marianna University School of Medicine, Toyoko Hospital |
|
Masataka Sumiyohsi |
Department of Cardiology, Juntendo University Nerima Hospital |
|
Ritsuko Kohno |
Department of Heart Rhythm Management, University of Occupational and Environmental Health |
04.HIF signaling and cardiovascular diseases
March 12 (Sat) 10:30-12:00 Track 7
Chairpersons: |
Norihiko Takeda |
Division of Cardiology and Metabolism, Center for Molecular Medicine, Jichi Medical University |
|
Masaomi Nangaku |
The University of Tokyo Graduate School of Medicine |
Speakers: |
Norihiko Takeda |
Division of Cardiology and Metabolism, Center for Molecular Medicine, Jichi Medical University |
|
Tetsuhiro Tanaka |
Division of Nephrology and Endocrinology, University of Tokyo School of Medicine |
|
Wataru Kimura |
RIKEN BDR |
05.Basic research in Pulmonary Hypertension
March 12 (Sat) 10:30-12:00 Track 9
Chairpersons: |
Aiko Ogawa |
National Hospital Organization Okayama Medical Center |
|
Utako Yokoyama |
Tokyo Medical University |
Speakers: |
Daniel Greif |
Yale University School of Medicine |
|
Yoshikazu Nakaoka |
Department of Vascular Medicine, National Cerebral and Cardiovascular Center Research Institute |
|
Hiroyoshi Y. Tanaka |
Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University |
|
Hirofumi Sawada |
Departments of Anesthesiology and Clitical Care Medicine and Pediatrics, Mie University |
06.New horizon of treatment for HOCM
March 12 (Sat) 10:30-12:00 Track 21
Chairpersons: |
Hiroaki Kitaoka |
Department of Cardiology and Geriatrics, Kochi University |
|
Carolyn Yung Ho |
Brigham and Women's Hospital, USA |
Keynote Lecture: |
|
Carolyn Yung Ho |
Brigham and Women's Hospital, USA |
Speakers: |
Toru Kubo |
Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University |
|
Itaru Takamisawa |
Sakakibara Heart Institute |
|
Shuichiro Takanashi |
Department of Cardiovascular Surgery, Kawasaki Saiwai Hospital |
07.To overcome myocarditis: Current state and future perspective
March 12 (Sat) 13:30-15:00 Track 5
Chairpersons: |
Takayuki Inomata |
Department of Cardiovascular Medicine, Niigata University School of Medical and Dental Sciences |
|
Takahiro Okumura |
Department of Cardiology, Nagoya University Graduate School of Medicine |
Speakers: |
Takeshi Ueda |
Department of Emergency and General Internal Medicine, Rakuwakai Marutamachi Hospital |
|
Kazufumi Nakamura |
Department of Cardiovascular Medicine, Okayama University |
|
Toshiyuki Nagai |
Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University |
|
Yasuhide Asaumi |
National Cerebral and Cardiovascular Center |
|
Akira Shiose |
Department of Cardiovascular Surgery, Kyushu University |
|
Enrico Ammirati |
De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy |
08.Life-course Approach to Pediatric Risk Factors for Cardiovascular Disease
March 12 (Sat) 13:30-15:00 Track 9
Chairpersons: |
Tetsuo Minamino |
Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University |
|
Samuel S. Gidding |
Geisinger Genomic Medicine Institute, USA |
Keynote Lecture: |
|
Samuel S. Gidding |
Geisinger Genomic Medicine Institute, USA |
Speakers: |
Keiji Matsunaga |
Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University |
|
Mariko Harada-Shiba |
Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center Research Institute |
|
Hayato Tada |
Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa |
|
Hanako Jimi |
Member of the House of Councilors |
09.Catheter-based treatment of mitral valve regurgitation
March 12 (Sat) 13:30-15:00 Track 22
Chairpersons: |
Kazuaki Tanabe |
Division of Cardiology, Shimane University Faculty of Medicine |
|
Paul Sorajja |
Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, USA |
Keynote Lecture: |
|
Paul Sorajja |
Valve Science Center, Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, USA |
Speakers: |
Hirotomo Sato |
Minneapolis Heart Institute Foundation |
|
Shunsuke Kubo |
Department of Cardiovascular Medicine, Kurashiki Central Hospital |
|
Masanori Yamamoto |
Toyohashi Heart Center |
|
Akihiro Isotani |
Kokura Memorial Hospital |
10.Molecular Mechanism of HFpEF
March 13 (Sun) 08:00-09:30 Track 8
Chairpersons: |
Osamu Yamaguchi |
Department of Cardiology, Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine |
|
Joseph A. Hill |
UT Southwestern Medical Center, USA |
Keynote Lecture: |
|
Joseph A. Hill |
UT Southwestern Medical Center, USA |
Speakers: |
Motoaki Sano |
Department of Cardiology, Keio University School of Medicine |
|
Shigehiro Ohdo |
Kyushu University |
|
Norihiko Takeda |
Jichi Medical University |
|
Shungo Hikoso |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
11.To Prevent the Collapse of Cardiovascular Care System in the Local Lesion
March 13 (Sun) 08:00-09:30 Track 13
Chairpersons: |
Naoyuki Hasebe |
Asahikawa Medical University, Department of Cardiovascular Renovation and Inovation |
|
Mitsuru Ohishi |
Cardiovascular Medicine and Hypertension, Kagoshima University |
Speakers: |
Masanari Kuwabara |
Ministry of Health, Labour and Welfare, Japan |
|
Daisuke Kanda |
Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University |
|
Toshiro Kitagawa |
Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima |
|
Naoki Nakagawa |
Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University |
|
Yoshihiro Takayama |
Division of Infectious Diseases, Okinawa Chubu Hospital |
|
Takafumi Ueno |
Department of Cardiology, Fukuoka Kinen Hospital |
12.Artificial Intelligence in Cardiology: Current Progress and Future Perspectives
March 13 (Sun) 10:30-12:00 Track 13
Chairpersons: |
Yukiko Nakano |
Hiroshima University |
|
Tetsuo Sasano |
Department of Cardiovascular Medicine, Tokyo Medical and Dental University |
Keynote Lecture: |
|
Paul A. Friedman |
Mayo Clinic, USA |
Speakers: |
Kenya Kusunose |
Department of Cardiovascular Medicine, Tokushima University Hospital |
|
Shinichi Goto |
Division of Cardiovascular Medicine, Brigham and Women's Hospital, USA |
|
Katsuhito Fujiu |
Department of Cardiovascular Medicine, the University of Tokyo |
|
Sanjiv J. Shah |
Division of Cardiology, Northwestern University Feinberg School of Medicine, USA |
13.Single cell analysis in cardiovascular disease
March 13 (Sun) 08:00-09:30 Track 22
Chairpersons: |
Kenji Onoue |
Cardiovascular Medicine, Nara Medical University |
|
Seitaro Nomura |
The University of Tokyo Hospital |
Keynote Lecture: |
|
Jonathan Butcher |
Biomedical Engineering, Cornell University, USA |
Speakers: |
Toshiyuki Ko |
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo |
|
Ryotaro Maeda |
Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine |
|
Jin Komuro |
Department of Cardiology, Keio University School of Medicine |
|
Takuo Emoto |
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University School of Medicine |
|
Ken Matsuoka |
Department of Medical Biochemistry, Osaka University Graduate School of Medicine |
14.Dawn of "Sports Cardiology" in Japan
March 13 (Sun) 10:30-12:00 Track 22
Chairpersons: |
Kousuke Fukao |
Juntendo University Faculty of Health and Sports Science |
|
Koji Nakagawa |
Department of Cardiovascular Medicine, Okayama University Hospital |
Speakers: |
Yoshitaka Iso |
Division of Cardiology, Department of Internal Medicine, Showa University Fujigaoka Hospital |
|
Tomohiro Manabe |
Sports Medicine Research Center, Keio University |
|
Kasuki Suruga |
National Hospital Organization Okayama Medical Center |
|
Norimitsu Kinoshita |
Faculty of Sports and Health Studies, Hosei University |
15.Non-alcoholic fatty liver disease - the heart of the matter
March 13 (Sun) 13:15-14:45 Track 8
Chairpersons: |
Shinji Koba |
Showa University |
|
Masahiro Koseki |
Division of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
Keynote Lecture: |
|
Laurence S. Sperling |
The Center for Heart Disease Prevention, Emory University School of Medicine, Atlanta, USA |
Speakers: |
Hirofumi Tomiyama |
Department of Cardiology, Tokyo Medical University, Tokyo |
|
Masato Furuhashi |
Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo |
|
Keishi Ichikawa |
Department of Cardiovascular Medicine, Okayama University Hospital |
|
Kotaro Kanno |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
16.New developments of iPS cell research
March 13 (Sun) 15:45-17:15 Track 8
Chairpersons: |
Yuji Shiba |
Department of Regenerative Science and Medicine, Shinshu University |
|
Katsuhisa Matsuura |
Tokyo Women’s Medical University |
Speakers: |
Yukihiro Saito |
Department of Cardiovascular Medicine, Okayama University Hospital |
|
Masamichi Ito |
Department of Cardiovascular Medicine, The University of Tokyo |
|
Takuma Takada |
Department of Cardiology, Tokyo Women’s Medical University |
|
Shin Kadota |
Department of Regenerative Science and Medicine, Shinshu University |
|
Yoshinori Yoshida |
Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University |
17.cGMP signaling in heart failure
March 13 (Sun) 13:15-14:45 Track 13
Chairpersons: |
Eiki Takimoto |
Department of Cardiovascular Medicine, The University of Tokyo |
|
Toshihisa Anzai |
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine |
Keynote Lecture: |
|
David A. Kass |
Johns Hopkins University School of Medicine, USA |
Speakers: |
Eiki Takimoto |
Department of Cardiovascular Medicine, The University of Tokyo |
|
Taishi Nakamura |
Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto University |
|
Hitoshi Nakagawa |
Nara Medical University Cardiovascular Medicine |
|
Koichiro Kuwahara |
Department of Cardiovascular Medicine, Shinshu University School of Medicine |
18.Integrated assessment of coronary imaging and physiology for optimal treatment of coronary artery disease
March 13 (Sun) 15:30-17:00 Track 13
Chairpersons: |
Shiro Uemura |
Department of Cardiovascular Medicine, Kawasaki Medical School |
|
Niels Holm |
Aarhus University Hospital, Denmark |
Keynote Lecture: |
|
Niels Holm |
Aarhus University Hospital, Denmark |
Speakers: |
Kiyoshi Hibi |
Yokohama City University Medical Center |
|
Fumiyasu Seike |
Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine |
|
Hitoshi Matsuo |
Gifu Heart Center |
|
Taishi Yonetsu |
Department of Cardiovascular Medicine, Tokyo Medical and Dental University |
19.Heart Failure in obesity, insulin resistance and diabetes
March 13 (Sun) 13:15-14:45 Track 19
Chairpersons: |
Junichi Sadoshima |
Rutgers New Jersey Medical School, USA |
|
Ippei Shimizu |
Juntendo University Graduate School of Medicine, Department of Cardiovascular Biology and Medicine |
Keynote Lecture: |
|
Junichi Sadoshima |
Rutgers New Jersey Medical School, USA |
Speakers: |
Agian J. Barinda |
Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Indonesia |
|
Shinichi Oka |
Cell Biology and Molecular Medicine, |
|
Adam Wende |
University of Alabama at Birmingham, USA |
|
Jin Han |
Inje University, Cardiovascular and Metabolic Disease Center, Korea |
20.Cardiac rehabilitation in severe heart failure
March 13 (Sun) 15:45-17:15 Track 19
Chairpersons: |
Koichiro Kinugawa |
University of Toyama |
|
Osamu Yamaguchi |
Department of Cardiology, Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine |
Speakers: |
Makiko Nakamura |
Second Department of Internal Medicine, University of Toyama |
|
Takeo Fujino |
Department of Cardiovascular Medicine, Kyushu University Hospital |
|
Eisuke Amiya |
Department of Therapeutic Strategy for Heart Failure, University of Tokyo |
|
Takehiro Okumura |
Department of Cardiology, Nagoya University Graduate School of Medicine |
|
Toru Miyoshi |
Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine |
|
Osamu Seguchi |
National Cerebral and Cardiovascular Center |
21.Organella-initiated cell death
March 13 (Sun) 13:15-14:45 Track 21
Chairpersons: |
Tomomi Ide |
Kyushu University |
|
Kinya Otsu |
National Cerebral and Cardiovascular Center |
Keynote Lecture: |
|
Kinya Otsu |
National Cerebral and Cardiovascular Center |
Speakers: |
Tomomi Ide |
Kyushu University |
|
Yuichi Oike |
Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University |
|
Shuhei Nakamura |
Institute for Advanced Co-Creation Studies, Osaka University |
Debate
01.TBD
March 11 (Fri) 08:00-09:00 Track 17
Chairpersons: |
Kazuo Tanemoto |
Kawasaki Medical School |
|
Masato Nakamura |
Toho University Ohashi Medical Center |
Speakers: |
Osamu Iida |
Cardiovascular Center, Kansai Rosai Hospital, Amagasaki |
|
Daisuke Akagi |
Department of Cardiovascular Surgery, Kawasaki Medical School |
|
Yasutaka Yamauchi |
Cardiovascular Center, Takatsu General Hospital, Kawasaki |
|
Toshifumi Kudo |
Division of Vascular Surgery, Department of Surgery, Tokyo Medical and Dental University |
02.Treat the Pump or Treat the Rhythm?
March 11 (Fri) 08:00-09:00 Track 18
Chairpersons: |
Atsuyuki Watanabe |
National Hospital Organization Okayama Medical Center Cardiology |
Speakers: |
Masaru Hatano |
Advanced Medical Center for Heart Failure |
|
Takafumi Sakamoto |
Department of Cardiovascular Medicine, Kyushu University Hospital |
|
Koichiro Ejima |
Department of Cardiology, Tokyo Women's Medical University |
03.Oral Anticoagulation Therapy for Very Elderly Patients with Atrial Fibrillation
March 11 (Fri) 09:45-10:45 Track 21
Chairperson: |
Ken Okumura |
Saiseikai Kumamoto Hospital |
|
Masaharu Akao |
National Hospital Organization Kyoto Medical Center |
Speakers: |
Yasuo Okumura |
Division of Cardiology, Department of Medicine, Nihon University School of Medicine |
|
Shinya Suzuki |
The Cardiovascular Institute |
|
Toshiya Ohtsuka |
Center of Wolf-Ohtsuka TTAF Procedure, New-Heart Watanabe International Institute |
04.MR due to IE, Repair or Replacement ?
March 11 (Fri) 09:45-10:45 Track 18
Chairpersons: |
Tatsuhiko Komiya |
Kurashiki Central Hospital Cardiovascular Surgery |
|
Hiroyuki Watanabe |
Tokyo Bay Urayasu/Ichikawa Medical Center |
Speakers: |
Tomoya Uchimuro |
Department of Cardiac Surgery, Kawasaki Saiwai Hospital |
|
Shuichiro Takanashi |
Department of Cardiovascular Surgery, Kawasaki Saiwai Hospital |
Panelists: |
Takeshi Kitai |
National Cerebral and Cardiovascular Center |
|
Tadaaki Koyama |
Kobe City Medical Center General Hospital |
|
Mitsuhiko Ota |
Toranomon Hospital Department of Cardiovascular Medicine |
05.Which drug is optimal after DAPT period? Aspirin, Clopidogrel or Prasugrel?
March 11 (Fri) 13:30-14:30 Track 17
Chairpersons: |
Takeshi Kimura |
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine |
|
Shinya Goto |
Department of Medicine (Cardiol), Tokai University School of Medicine |
Speakers: |
Shinya Goto |
Department of Medicine (Cardiol), Tokai University School of Medicine |
|
Masato Nakamura |
Toho University Ohashi Medical Center |
|
Masahiro Natsuaki |
Department of Cardiology, Saga University |
06.TBD
March 11 (Fri) 14:30-15:30 Track 17
Chairpersons: |
Nozomi Watanabe |
Division of Cardiovascular Physiology, University of Miyazaki Faculty of Medicine |
|
Yukio Abe |
Department of Cardiology, Osaka City General Hospital |
Speakers: |
Shunsuke Kubo |
Department of Cardiovascular Medicine, Kurashiki Central Hospital |
|
Hidekazu Tanaka |
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine |
|
Tomohiro Sakamoto |
Saiseikai Kumamoto Hospital Cardiovascular Center |
|
Yasushi Sakata |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
07.Does Early Participation of Adult Cardiologists Improve the Prognosis Patients with Fontan Circulation ?
March 12 (Sat) 08:00-09:00 Track 12
Chairpersons: |
Ichiro Sakamoto |
Department of Cardiovascular Medicine, Kyushu University Hospital |
|
Hideo Ohuchi |
National Cerebral and Cardiovascular Center |
Speakers: |
Hideo Ohuchi |
National Cerebral and Cardiovascular Center |
|
Norihisa Toh |
Department of Cardiovascular Medicine, Okayama University |
|
Eriko Shimada |
Department of Pediatric Cardiology and Adult Congenital Cardiology, Tokyo Women's Medical University |
|
Ichiro Sakamoto |
Department of Cardiovascular Medicine, Kyushu University Hospital |
08.Exercise for Older Patients with Heart Failure: Should They Do Aerobic Exercise or Resistance Exercise ?
March 12 (Sat) 13:30-14:30 Track 15
Chairpersons: |
Shin-ichiro Miura |
Department of Cardiology, Fukuoka University School of Medicine |
|
Tetsuya Takahashi |
Juntendo University |
Speakers: |
Kanta Fujimi |
Department of Rehabilitation, Fukuoka University Hospital |
|
Akio Honzawa |
Cardiovascular Rehabilitation and Fitness, Juntendo University Hospital |
|
Hitoshi Adachi |
Gunma Prefectural Cardiovascular Center |
|
Yuji Kono |
Department of Rehabilitation, Fujita Health University Hospital |
Topics
01.New horizon of ion channel functions in arrhythmic syndromes
March 11 (Fri) 09:45-10:45 Track 7
Chairpersons: |
Naomasa Makita |
National Cerebral and Cardiovascular Center |
|
Toshihiro Tanaka |
BioResource Research Center, Tokyo Medical and Dental University (TMDU) |
Speakers: |
Seiko Ohno |
Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center |
|
Takeru Makiyama |
Department of Community Medicine Supporting System, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine |
02.Intensitive therapy for refractory ventricualr tachyarrhyhtmias, up to date
March 11 (Fri) 09:45-10:45 Track 8
Chairpersons: |
Kyoko Soejima |
Kyorin University |
|
Takumi Yamada |
University of Minnesota, USA |
Keynote Lecture: |
|
Takumi Yamada |
University of Minnesota, USA |
|
Roderic Tung |
The Univesity of Chicago Department of Medicine, USA |
Speakers: |
Yasuteru Yamauchi |
Japan Redcross Yokohama City Bay Hospital |
|
Miyako Igarashi |
Department of Cardiology, Faculty of Medicine, University of Tsukuba |
03.Electrophysiology meets atrial anatomy: atrial structure-related arrhythmias
March 11 (Fri) 09:45-10:45 Track 9
Chairpersons: |
Taka-aki Matsuyama |
Department of Legal Medicine, Showa University School of Medicine |
|
Peng-Sheng Chen |
Cedars-Sinai Medical Center, USA |
Keynote Lecture: |
|
Peng-Sheng Chen |
Cedars-Sinai Medical Center, USA |
Speakers: |
Igor R. Efimov |
Department of Biomedical Engineering, The George Washington University, USA |
|
Kenta Tsutsui |
Department of Cardiovascular Medicine, Saitama Medical University International Medical Center, Hidaka |
|
Shumpei Mori |
UCLA Cardiac Arrhythmia Center, USA |
|
Kennosuke Yamashita |
Department of Caradiology, Sendai Kousei Hospital |
04.A new era of congenital cardiac surgery: improving ultra-long-term outcomes
March 11 (Fri) 09:45-10:45 Track 10
Chairpersons: |
Shingo Kasahara |
Department of Cardiovascular Surgery, Okayama University |
|
Osami Honjo |
The Labatt Family Heart Centre, The Hospital for Sick Children, Department of Surgery, University of Toronto, Translational Medicine, Research Institute, Canada |
Speakers: |
Osami Honjo |
The Labatt Family Heart Centre, The Hospital for Sick Children, Department of Surgery, University of Toronto, Translational Medicine, Research Institute, Canada |
|
Takaya Hoashi |
National Cerebral and Cardiovascular Center |
|
Yasutaka Hirata |
Department of Cardiac Surgery, The University of Tokyo Hospital |
05.Shared Care in the Field of Advanced Heart Failure
March 11 (Fri) 09:45-10:45 Track 11
Chairpersons: |
Shinichi Nunoda |
Department of Therapeutic Strategy for Severe Heart Failure, Graduate School of Medicine, Tokyo Women's Medical University |
|
Norihide Fukushima |
Department of Transplant Medicine, National Cerebral and Cardiovascular Center |
Speakers: |
Yasumasa Tsukamoto |
National Cerebral and Cardiovascular Center |
|
Yuki Ichihara |
Department of Cardiovascular Surgery, Tokyo Women's Medical University |
|
Tomonori Ooka |
Department of Cardiovascular and Thoracic Surgery, Hokkaido University Graduate School of Medicine |
|
Miki Akiba |
Tohoku University Hospital Organ Transplantation Center |
|
Koichiro Kinugawa |
University of Toyama, Toyama |
|
Shogo Oishi |
Department of Cardiology, Himeji Cardiovascular Center |
06.Up-to-date Overview on Anemia Management in Cardio-renal-anemia Syndrome
March 11 (Fri) 09:45-10:45 Track 13
Chairpersons: |
Masanori Asakura |
Hyogo College of Medicine |
|
Toshihisa Anzai |
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine |
Speakers: |
Yoshiro Naito |
Department of Cardiovascular and Renal Medicine, Hyogo College of Medicine |
|
Kazuya Nagao |
Department of Cardiology, Japan Red Cross Osaka Hospital |
|
Toshiyuki Nagai |
Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University |
|
Nobuhiko Joki |
Division of Nephrology, Toho University Ohashi Medical Center |
07.Myocardial disease approaching by diagnostic imaging (cardiac amyloidosis、cardiac sarcoidosis、DCM etc.)
March 11 (Fri) 09:45-10:45 Track 15
Chairpersons: |
Yasuhiro Izumiya |
Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine |
|
Jae K. Oh |
Mayo Clinic, USA |
Keynote Lecture: |
|
Jae K. Oh |
Mayo Clinic, USA |
Speakers: |
Takeru Nabeta |
Department of Cardiovascular Imaging, Leiden University Medical Center, The Netherlands |
|
Kenji Fukushima |
Fukushima Medical University |
|
Seitaro Oda |
Department of Diagnostic Radiology, Kumamoto University Hospital |
08.Percutaneous pulmonary valve replacement: Patient selection and initial outcomes
March 11 (Fri) 09:45-10:45 Track 19
Chairpersons: |
Masaaki Yamagishi |
Department of Pediatric Cardiovascular Surgery, Kyoto Prefectural University of Medicine |
|
Satoshi Yazaki |
Sakakibara Heart Institute |
Speakers: |
Terunobu Fukuda |
Department of Medicine, Division of Cardiology, Kobe University Graduate School of Medicine |
|
Yasutaka Hirata |
Department of Cardiac Surgery, The University of Tokyo Hospital, Tokyo |
|
Mike Saji |
Sakakibara Heart Institute, Adult Congenital Heart Disease Center |
|
Hisayuki Hongu |
Department of Pediatric Cardiovascular Surgery, Children's Medical Center, Kyoto Prefectural University of Medicine |
|
Kazuto Fujimoto |
Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center |
09.Prospective Approach of the Therapy for Pulmonary Arterial Hypertension
March 11 (Fri) 09:45-10:45 Track 20
Chairpersons: |
Hiromi Matsubara |
National Hospital Organization Okayama Medical Center |
|
Noriaki Emoto |
Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University |
Keynote Lecture: |
|
Alexander M.K. Rothman |
The University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, UK |
Speakers: |
Alexander Edemskiy |
Novosibirsk Research Institute of Circulation Pathology |
|
Yoshikazu Nakaoka |
Department of Vascular Medicine, National Cerebral and Cardiovascular Center Research Institute |
|
Noriaki Emoto |
Laboratory of Clinical Pharmacy, Kobe Pharmaceutical University |
10.Multiple Organ Damage in Heart Failure: Current Topics
March 11 (Fri) 09:45-10:45 Track 23
Chairpersons: |
Yoshihiro Seo |
Department of Cardiology Nagoya City University Graduate School of Medical Sciences |
|
Yasushi Sakata |
Cardiovascular Medicine, Osaka University Graduate School of Medicine |
Speakers: |
Shuichi Kitada |
Department of Cardiology, Nagoya City University Graduate School of Medical Sciences |
|
Masahiro Koseki |
Division of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Shintaro Kinugawa |
Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University |
|
Tomoya Yamashita |
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe |
11.Robotic PCI from A to Z
March 11 (Fri) 13:30-14:30 Track 5
Chairpersons: |
Ehtisham Mahmud |
University of California, San Diego, USA |
|
Takafumi Ueno |
Fukuoka Kinen Hospital |
Keynote Lecture: |
|
Ehtisham Mahmud |
University of California, San Diego, USA |
Speakers: |
Yoshihiro Morino |
Iwate Medical University |
|
Yoshiaki Mitsuake |
Division of Cardiovascular Medicine, Kurume University School of Medicine |
|
Tejas M. Patel |
Apex Heart Institute, Ahmedabad, India |
12.What is atrial cardiomyopathy?
March 11 (Fri) 13:30-14:30 Track 6
Chairpersons: |
Mikiko Nakagawa |
Medical Education Center, Oita University |
|
Takeshi Yamashita |
The Cardiovascular Institute, Tokyo |
Keynote Lecture: |
|
Takeshi Yamashita |
The Cardiovascular Institute, Tokyo |
Speakers: |
Taka-aki Matsuyama |
Department of Legal Medicine, Showa University School of Medicine |
|
Takanori Yamaguchi |
Department of Cardiovascular Medicine, Saga University |
|
Tomoko Ishizu |
Department of Cardiology, University of Tsukuba |
|
Ichitaro Abe |
Department of Cardiology and Clinical Examination, Oita University Faculty of Medicine, Oita |
13.Novel pacing therapy for heart failure(His LV Multipoint etc)
March 11 (Fri) 13:30-14:30 Track 7
Chairpersons: |
Toshiaki Sato |
Kyorin University, School of Medicine, Division of Advanced Arrhythmia Management |
|
Takashi Kurita |
Cardiovascular Center, Kindai University |
Keynote Lecture: |
|
Pugazhendhi Vijayaraman |
Geisinger Heart Institute, Wilkes-Barre, Pennsylvania, USA |
Speakers: |
Nobuhiro Nishii |
Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences |
|
Shinji Mito |
Chikamori Hospital |
|
Hiroyuki Kato |
Division of Cardiology, JCHO Chukyo Hospital |
14.Take a fun Quiz on the Latest Guidelines for CPR and ECC (2020 AHA Guidelines)
March 11 (Fri) 13:30-14:30 Track 19
Chairpersons: |
Migaku Kikuchi |
Dokkyo Medical University |
|
Takeshi Yamamoto |
Division of Cardiovascular Intensive Care, Nippon Medical School Hospital |
Speakers: |
Hiroshi Takahashi |
Steel Memorial Muroran Hospital |
|
Hiroyuki Hanada |
Advanced Emergency and Clitical Care Center, Hirosaki University Hospital |
|
Toshikazu Funazaki |
Saiseikai Kawaguchi General Hospital |
|
Yoshio Tahara |
National Cerebral and Cardiovascular Center |
15.Learn BLS & ACLS with Fun! A Quiz Session
March 11 (Fri) 16:00-17:00 Track 19
Chairpersons: |
Hironori Saito |
Japanese Red Cross Okayama Hospital |
|
Hiromi Seo |
Kochi Medical School |
Speakers: |
Migaku Kikuchi |
Dokkyo Medical University |
|
Yoshio Tahara |
National Cerebral and Cardiovascular Center |
16.Cardiovascular Imaging to Enhance Prevention
March 13 (Sun) 08:00-09:00 Track 12
Chairpersons: |
Toru Miyoshi |
Okayama University Hospital |
|
Matthew J. Budoff |
UCLA School of Medicine, USA |
Keynote Lecture: |
|
Matthew J. Budoff |
UCLA School of Medicine, USA |
Speakers: |
Kazuhiro Osawa |
Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center, Okayama |
|
Hidenobu Takagi |
Department of Radiology, Tohoku University Hospital |
|
Rine Nakanishi |
Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Toho University Medical Center, Omori Hospital, Tokyo |
17.Role of non-cording RNAs in cardiovascular diseases
March 13 (Sun) 09:00-10:00 Track 12
Chairpersons: |
Koh Ono |
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine |
|
Toyoaki Murohara |
Nagoya University |
Speakers: |
Takahiro Horie |
Department of Cardiovascular Medicine, Kyoto University |
|
Yuichi Oike |
Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University |
18.Challenging of Home Medical Care for Heart Failure
March 13 (Sun) 10:30-11:30 Track 12
Chairpersons: |
Dai Yumino |
Yumino Medical |
|
Mari Ito |
Kawasaki Medical School General Medical Center |
Speakers: |
Hiroki Ito |
Aoba Clinic |
|
Akihiro Sakashita |
Division of Palliative Medicine, Department of Internal Medicine, Hyogo Brain and Heart Center |
|
Kayoko Murazaki |
|
|
Keiko Saito |
Yumino Heart Clinic |
19.Treatment of hypertension in Society 5.0
March 13 (Sun) 10:30-11:30 Track 15
Chairpersons: |
Mari Ishida |
Department of Cardiovascular Physiology and Medicine, Hiroshima University |
|
Takuya Kishi |
Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare |
Speakers: |
Kazuomi Kishi |
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine |
|
Takuya Kishi |
Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare |
|
Yasushi Okuno |
Dept. of Biomed. Data Intelligence, Grad.Sch. of Med., Kyoto Univ. |
20.Stress Echocardiography: When, for Whom, and for What ?
March 13 (Sun) 15:45-16:45 Track 7
Chairpersons: |
Hirotsugu Yamada |
Tokushima University Graduate School of Biomedical Sciences, Community Medicine for Cardiology |
|
Yutaka Hirano |
Central Clinical Laboratory, Kindai University Hospital |
Speakers: |
Tadafumi Sugimoto |
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine |
|
Masaki Izumo |
St. Marianna University School of Medicine |
|
Hiroto Utsunomiya |
Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences |
|
Masaru Obokata |
Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine |
|
Kenya Kusunose |
Department of Cardiovascular Medicine, Tokushima University Hospital, Tokushima |
21.State-of-the-art treatment for AAA/TAA
March 13 (Sun) 13:15-14:15 Track 15
Chairpersons: |
Hitoshi Ogino |
Tokyo Medical University |
|
Kenji Okada |
Division of Cardiovascular Surgery, Kobe University Graduate School of Medicine |
Speakers: |
Takanori Tsujimoto |
Department of Cardiovascular Surgery, Kobe University School of Medicine |
|
Takao Ohki |
Jikei University, Department of Surgery |
|
Hitoshi Matsuda |
Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center |
|
Makoto Kinoshita |
Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital |
|
Nobuyoshi Azuma |
Department of Vascular Surgery, Asahikawa Medical University |
22.Secondary Prevention of ASCVD: Beyond LDL
March 13 (Sun) 15:30-16:30 Track 18
Chairpersons: |
Satoshi Yasuda |
Tohoku University Graduate School of Medicine |
|
Masaaki Kawashiri |
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kanazawa University |
Speakers: |
Yu Kataoka |
National Cerebral and Cardiovascular Center |
|
Kazuma Oyama |
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine |
|
Ryuji Toh |
Division of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine |
|
Hayato Tada |
Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa |
Meet the Expert
01.Frontier of molecular imaging
March 11 (Fri) 09:45-10:45 Track 5
Chairpersons: |
Takahiro Higuchi |
Julius-Maximilians-Universitaet of Wuerzburg, Germany |
|
Jonathan R. Lindner |
Oregon Health and Science University, USA |
Keynote Lecture: |
|
Jonathan R. Lindner |
Oregon Health and Science University, USA |
Speaker: |
Takahiro Higuchi |
Department of Nuclear Medicine, CHFC, University of Wuerzburg, Germany |
02.Echocardiography for management of structural heart diseases
March 11 (Fri) 09:45-10:45 Track 6
Chairpersons: |
Hikaru Tsuruta |
Keio University School of Medicine |
|
Nozomi Watanabe |
Cardiovascular Physiology, University of Miyazaki Faculty of Medicine |
Speaker: |
Masaki Izumo |
St. Marianna University School of Medicine |
|
Hikaru Tsuruta |
Keio University School of Medicine |
03.Pregnancy in Adult Congenital Heart Disease – A Management Dilemma between Guidelines and Clinical Practice
March 11 (Fri) 09:45-10:45 Track 12
Chairpersons: |
Shinji Katsuragi |
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Miyazaki |
|
Hirohiko Motoki |
Department of Cardiovascular Medicine, Shinshu University School of Medicine |
Speakers: |
Chizuko Kamiya |
Department of Obstetrics and Gynecology, National Cerebral and Cardiovascular Center |
|
Ichiro Sakamoto |
Department of Cardiovascular Medicine, Kyushu University Hospital |
04.Optimal Therapeutic Strategy for Heavily Calcified Lesion
March 11 (Fri) 09:45-10:45 Track 14
Chairpersons: |
Yoshio Kobayashi |
Department of Cardiovascular Medicine, Chiba Graduate School of Medicine |
|
Yoshihide Fujimoto |
International University of Health and Welfare Narita Hospital |
Speakers: |
Kenichi Sakakura |
Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University |
|
Yoshisato Shibata |
Department of Cardiology, Miyazaki Medical Association Hospital |
05.Exercise – based Physical Therapy for Frail Patients with Cardiovascular Disease
March 11 (Fri) 09:45-10:45 Track 22
Chairpersons: |
Minako Yamaoka-Tojo |
Kitasato University |
|
Takanori Yasu |
Dokkyo Medical University Nikko Medical Center |
Speakers: |
Hideo Izawa |
Department of Cardiology, Fujita Health University School of Medicine |
|
Sumio Yamada |
Nagoya University Graduate School of Medicine (Integrated Health Sciences) |
06.Antiarrhythmic Medication Revised: How to Use Medication in the Catheter Ablation Era ?
March 11 (Fri) 09:45-10:45 Track 24
Chairpersons: |
Naohiko Takahashi |
Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University |
|
Naokata Sumitomo |
Saitama Medical University International Medical Center |
Speakers: |
Takeshi Yamashita |
The Cardiovascular Institute |
|
Yu-ki Iwasaki |
Department of Cardiovascular Medicine, Nippon Medical School |
07.Remote monitoring to change heart failure management
March 11 (Fri) 16:00-17:00 Track 16
Chairpersons: |
Nobuhiro Nishii |
Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences |
|
Norihiko Kotooka |
Saga University |
Keynote Lecture: |
|
Friedrich Koehler |
Charité Universitätsmedizin Berlin, Germany |
Speaker: |
Tetsuya Kaneko |
Saga university, Department of Cardiovascular Medicine |
08.New topics in inherited arrhythmic syndrome and cardiomyopathies
March 13 (Sun) 13:15-14:15 Track 12
Chairpersons: |
Takeshi Aiba |
National Cerebral and Cardiovascular Center |
|
Takeru Makiyama |
Department of Community Medicine Supporting System, Kyoto University Graduate School of Medicine |
Keynote Lecture: |
|
Arthur Arnold Maria Wilde |
Heart Centre, Amsterdam University Medical Centres, location AMC, The Netherlands |
Speaker: |
Seiko Ohno |
Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center |
09.Vascular function test and preventive medicine
March 13 (Sun) 14:15-15:15 Track 12
Chairpersons: |
Yukihito Higashi |
Research Institute for Radiation Biology and Medicine, Hiroshima University |
|
Teruo Inoue |
Center for Advanced Medical Science Research, Dokkyo Medical University |
Keynote Lecture: |
|
Naomi M. Hamburg |
Boston University, USA |
Speaker: |
Toru Miyoshi |
Okayama University |
10.Multi-modality imaging for assessing right heart function in adult congenital heart disease
March 13 (Sun) 15:30-16:30 Track 12
Chairpersons: |
Tomoko Ishizu |
Department of Cardiology, University of Tsukuba |
|
Yumi Shiina |
St. Luke's International Hospital, Cardiovascular Center |
Speakers: |
Kenichiro Yamamura |
Department of Perinatal and Pediatric Medicine, Graduate School of Medical Sciences, Kyushu University |
|
Ryo Inuzuka |
Department of Pediatrics, University of Tokyo |
11.How to tackle structural valve deterioration
March 13 (Sun) 15:00-16:00 Track 16
Chairpersons: |
Minoru Tabata |
Department of Cardiovascular Surgery, Juntendo University |
|
Kentaro Hayashida |
Department of Cardiology, Keio University School of Medicine |
Speakers: |
Kazuo Shimamura |
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine |
|
Michael Lee |
Queen Elizabeth Hospital |
12.The heart team approach to atrial functional mitral regurgitation
March 13 (Sun) 16:00-17:00 Track 16
Chairpersons: |
Toshihiko Shibata |
Cardiovascular Surgery, Osaka City University |
|
Masao Daimon |
The University of Tokyo Hospital |
Speakers: |
Yukio Abe |
Department of Cardiology, Osaka City General Hospital |
|
Yosuke Takahashi |
Department of Cardiovascular Surgery, Osaka City University |
JCS/U45 ISHR Joint Symposium
March 13 (Sun) 10:30-12:00 Track 17
Chairpersons: |
Hidetaka Kioka |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Kyung-Duk Min |
Hyogo College of Medicine |
Speakers: |
Taijyu Satoh |
Tohoku University Graduate School of Medicine, Department of Cardiovascular Medicine |
|
Koji Yoshie |
Department of Cardiovascular Medicine, Shinshu University School of Medicine |
|
Seitaro Nomura |
The University of Tokyo Hospital |
|
Haruki Shinomiya |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Yasutomi Higashikuni |
Department of Cardiovascular Medicine, The University of Tokyo |
|
Takahiro Horie |
Department of Cardiovascular Medicine, Kyoto University |
Discassants: |
|
Shunsuke Katsuki |
Department of Cardiovascular Medicine, Kyushu University Hospital |
|
Yusuke Takahashi |
Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center |
Young Investigator's Award
01.Young Investigator's Award Finalists Lectures (Basic Research)
March 11 (Mon) 13:30-15:30 Track 16
Chairperson: |
Ichiro Shiojima |
Cardiology, Nephrology, and Endocrinology and Metabolism Kansai Medical Universitye |
Speakers: |
Masamichi Ito |
Department of Advanced Clinical Medicine, Graduate School of Medicine, the University of Tokyo, Tokyo |
|
Koji Yoshie |
Department of Cardiovascular Medicine, Shinshu University School of Medicine |
|
Hiroyasu Inui |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Hiroyuki Inoue |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Fujiwara Takayuki |
Department of Cardiovascular Medicine, The University of Tokyo |
02.Young Investigator's Award Finalists Lectures (Clinical Research)
March 11 (Mon) 08:00-10:00 Track 16
Chairperson: |
Junya Ako |
Cardiology, Nephrology, and Endocrinology and Metabolism Kansai Medical Universitye |
Speakers: |
Takuo Emoto |
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University School of Medicine, Kobe |
|
Yasuaki Shiraishi |
Department of Cardiology, Keio University School of Medicine |
|
Yasuhiro Hamatani |
Department of Cardiology, National Hospital Organization Kyoto Medical Center |
|
Tomohiro Hayashi |
Section of Arrhythmia, Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine |
03.Young Investigator's Award for International Students Finalist Lectures
March 12 (Sat) 08:00-10:00 Track 09
Chairperson: |
Keiichi Fukuda |
Cardiology Keio University |
Speakers: |
Mollal Md Rasel |
Shiga University of Medical Science |
|
Qing Liu |
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo |
|
Jiaxi Guo |
The University of Tokyo |
|
Chanthra Nawin |
Division of Regenerative Medicine, Jichi Medical University |
04.International Young Investigator’s Award Finalist Lectures (Basic Research)
March 12 (Sat) 08:00-09:30 Track 10
Chairperson: |
Koji Maemura |
Nagasaki University |
Speakers: |
Yusuke Kimishima |
Department of Cardiovascular Medicine, Fukushima Medical University |
|
Hideaki Inazumi |
Department of Cardiovascular Medicine, Kyoto University, Graduate School of Medicine |
|
Da Eun Roh |
Kyungpook National University Children's Hospital |
|
Lean Seng Chen |
Sarawak Heart Center |
|
Chien-Te Ho |
Chang Gung Memorial Hospital Linkuo Main Branch |
05.International Young Investigator’s Award Finalist Lectures (Clinical Research)
March 12 (Sat) 10:30-12:00 Track 10
Chairperson: |
Junya Ako |
Department of Cardiovascular Medicine Kitasato University School of Medicine |
Speakers: |
Ryan Leow |
National University Health System |
|
Hokyou Lee |
Yonsei University College of Medicine |
|
Chih-Min Liu |
Heart Rhythm Center, Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital |
|
Keita Koseki |
Cedars-Sinai Medical Center, Smidt Heart Institute |
|
Atsushi Sugiura |
University Hospital Bonn |
Special Lecure by International Honorary Members
01.Special Lecure by International Honorary Members
March 12 (Sat) 16:00-17:30 Track 09
Chairpersons: |
Yasushi Sakata |
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine |
|
Takashi Akasaka |
Department of Cardiovascular Medicine, Wakayama Medical University, Japan |
Speakers: |
Alain Cribier |
Department of Cardiology, Charles Nicolle Hospital University of Rouen, France |
|
Patrick W. Serruys |
National University of Ireland Galway, Ireland |
JIYC Original Session
01.What we learn from 2021 ESC heart failure guidelines - Case-based discussion by JIYC -
March 11 (Fri) 16:00-17:30 Track 17
Chairpersons: |
Toshiyuki Nagai |
Cardiovascular Medicine Hokkaido University Faculty of Medicine |
|
Rosita Zakeri |
School of Cardiovascular Medicine & Sciences King's College London |
Keynote Lecture: |
|
Rosita Zakeri |
School of Cardiovascular Medicine & Sciences King's College London |
Speakers: |
Yasuyuki Shiraishi |
Department of Cardiology, Keio University School of Medicine |
|
Masaru Obokata |
Department of Cardiovascular medicine Gunma University |
|
Takeo Fujino |
Cardiovascular Medicine Kyushu University |
Discassants: |
|
Tomofumi Misaka |
Department of Cardiovascular Medicine Fukushima Medical University |
|
Tze-Fan Chao |
National Yang Ming Chiao Tung University |
|
Yasuhiro Hamatani |
National Hospital Organization Kyoto Medical Center |
|
Hideaki Suzuki |
Department of Cardiovascular Medicine Tohoku University |
On-demand Session
01.Japan Heart Foundation Satoh Memorial Award Lecture
Chairperson: |
Hiroshi Ito |
Department of Cardiovascular Surgery Okayama University Graduate School of Medicine, Okayama |
Speakers: |
Katsuhito Fujiu |
Department of Cardiovascular Medicine, the University of Tokyo, Tokyo |
02.AHA ECC-JCS Joint Symposium
Chairpersons: |
Takeshi Yamamoto |
Cardiovascular Intensive Care Unit Nippon Medical School Hospital |
|
Mary Fran Hazinski |
Vanderbilt University, Nashville |
Speakers: |
Sunao Kojima |
Sakura-jyuji Yatsushiro Rehabilitation Hospital/Kumamoto University |
|
Tesuya Matoba |
Cardiology KYUSHU UNIVERSITY HOSPITAL |
|
Erin Bohula |
Brigham & Womens Hospital, Boston, Massachusetts |
03.CJ/EHJ Joint Session
Chairpersons: |
Toshihisa Anzai |
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine |
Speakers: |
Atsushi Kyodo |
|
|
Shungo Hikoso |
Wake County Government |
|
Rudolf De Boer |
Translational Cardiology, University Medical Center Groningen |
04.Circulation Journal Award Session
Chairperson: |
Toshihisa Anzai |
Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine |
Speakers: |
Yu Izawa |
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine |
|
Jun Yoshida |
Cedars-Sinai Medical Cente, Smidt Heart Institute |
|
Yoshihiro Seo |
Department of Cardiology, Nagoya City University Graduate School of |
|
Jun Hata |
Department of Epidemiology and Public Health, Graduate School of Medical Sciences,Kyushu University |
|
Yuichi Kimuta |
Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University |
|
Tomomi Matsuura |
Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences |
|
Mu-Chieh Chi |
Department of Medicine, Chang Gung University |